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ABSTRACT
Although the molecular mechanisms underlying lymphangiogenesis associated with
breast cancer continue to remain insufficiently understood, a growing body of evidence
suggests that many of the currently unknown answers revolve around the crosstalk
between the lymphangiogenic factor VEGF-C and chemokines. The present study
proposed the CCL21/CCR7 chemokine axis as a regulatory mechanism of VEGF-C
mediated breast cancer-induced lymphangiogenesis. In order to address the hypothesis,
the positive correlations between CCR7 signalling and VEGF-C expression/secretion by
MDA-MB-231 cells were sought, along with the molecular mechanism underlying their
correlation. Furthermore, the direct effect of CCL21/CCR7 interaction on lymphatic
endothelial cells (LECs) was tested through a series of in vitro lymphangiogenic assays.
CCL21/CCR7 axis has been found to regulate lymphangiogenesis in two distinct ways: i)
directly, through stimulation of the lymphangiogenic traits of LECs; and ii) indirectly,
through the promotion of VEGF-C secretion by breast cancer cells. These results suggest
a novel role of the CCL21/CCR7 axis in the promotion of breast cancer-induced
lymphangiogenesis.

KEYWORDS: CCL21 chemokine, CCR7 chemokine receptor, vascular endothelial
growth factor-C, phosphatidylinositol 3-kinase, protein kinase B, lymphangiogenesis,
breast cancer.
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1.1

Breast Cancer Overview
Breast cancer represents the most common form of malignancy among women

worldwide. Recent epidemiologic data indicate that mammary tumors have the highest
incidence and mortality rates among females, accounting in 2008, for 23% (1.38 million)
of total cancers and 14% (458,400) of total cancer deaths, respectively (Ferlay et al.,
2010). While approximately half of the new breast cancer cases and 60% of their related
deaths occur in developed countries (Western and Northern Europe, Australia/New
Zealand, and North America), the numbers decrease to low levels in sub-Saharan Africa
and Asia. However, unlike in the past decade, breast cancer is now regarded as the
leading cause of cancer death in both economically developed and developing countries
(Jemal et al., 2011).
The large statistical differences between developed and developing countries
can be attributed to reproductive and hormonal factors, as well as to early detection and
available treatment options. It is important to outline that despite the high breast cancer
incidence rates recorded in developed countries, the associated mortality rates seems to
have reached a plateau between 1960 and 1990, followed even by notable declines in
Northern Europe (WHO, 2008). Due to national mammographic screening programs and
advances in therapy, the survival rates in these countries have risen to 85% compared to
only 50-60% in the rest of the world, which continues to experience a slow growth in
both breast cancer incidence and mortality rates (WHO, 2008; Parkin et al., 2008).
Statistical data show that approximately 80% of breast malignancies develop
from ductal epithelium, while only a small proportion begin their development in the
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lobular epithelium (WHO, 2008). Despite the prognosis advantages offered by early
detection and diagnosis, unfortunately only about 60% of breast cancers are detected at a
local stage (Eccles et al., 2007), while the rest are characterized by various degrees of
metastatic dissemination.
Traditionally, the metastatic spread of breast carcinomas has been explained on
the basis of sequential progression involving the initial invasion of the local blood
vasculature followed by subsequent distribution, deposition and development at remote
sites (Karnoub and Weinberg, 2006). Similar to many other types of cancers, breast
tumors tend to metastasize initially into the regional lymph nodes, a process that typically
is followed by dissemination into distant organs. Generally, breast cancers are
characterized by increased invasiveness and versatility in metastatic mechanism, which
make them able to spread to a wide range of locations within the body.
While colonization of many of the remote sites can be explained - at least in
part - by their anatomical proximity and exposure to blood circulatory system, this
cannot constitute the basis of the frequency of breast cancer metastasis. Many researchers
consider that this represents in fact a strong indication that breast tumors also spread
through the alternate systemic pathways that are more or less independent from blood
vasculature. One of the most anatomically feasible options in this sense can be
constituted by lymphatics.

4

1.2

The Lymphatic Vascular System

1.2.1

Anatomy and Physiology of the Lymphatics
The lymphatic system constitutes a hierarchically-organized network of vessels

that unidirectionally transports a protein-rich fluid extravasated from the cardiovascular
system (Tammela et al., 2005). Lymphatic vessels have a universal distribution in all
vascularized tissues with the exception of the central nervous system, bone marrow,
retina, and placenta. The absence of lymphatics in the body is practically incompatible
with life, and their dysfunctionality often translates into chronic edema and/or impaired
immune responses (Tammela and Alitalo, 2010). Unlike the blood vascular system, the
lymphatic network is characterized by an open ended circulatory structure that starts
peripherally with blind-end capillaries and increases gradually to large vessel diameters
that eventually interlink with the venous system (Sundar and Ganesan, 2007). Besides
capillaries, the taxonomy of lymphatic architecture includes pre-collecting vessels that
provide a link between capillaries and larger collecting vessels, lymph nodes, trunks, and
ducts (Liersch et al., 2010).
Finger shaped lymphatic capillaries are characterized by relatively small
diameters (30 - 80 microns) and are lined by a single layer of thin-walled lymphatic
endothelial cells that lack pericytes or smooth muscle cells, have incomplete or no
basement membrane, and display distinct gene expression patterns (Alitalo et al., 2005;
Maby-El Hajjami and Petrova, 2008; Wick et al., 2007). In the absence of basal
membrane, smooth muscle cells, or tight cell-cell junctions, lymphatic capillaries connect
and stabilize their shape through very thin fibrillin-containing filaments anchored in the
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neighboring extracellular matrix (Alitalo et al., 2005). While the lumen of the lymphatic
capillaries is closed during physiological conditions, the aforementioned filaments
become activated under the increased pressure conditions associated with tissue
swelling/inflammation and thus favor interstitial fluid drainage by preventing the
lymphatic capillary from collapsing. The interconnections between lymphatic endothelial
cells (LECs) are present in the form of highly specialized discontinuous “button-like”
connections comprised of specialized adherens and tight junctions (Witte et al., 2011)
that facilitate interstitial protein drainage/uptake and immune cells transmigration (Baluk
et al., 2007; Tammela et al., 2007; Dejana et al., 2009). These “button-like” connections
provide lateral anchoring for the overlapping flap borders of oak leaf shaped LECs
(Dejana et al., 2009). This particular type of overlapping EEC junction also fulfils a
lymph flow regulatory role due to its dual valve functionality that prevents both
intralymphatic and interstitial backflows. Unlike capillaries, the walls of collecting
lymphatic vessels are characterized by continuous “zipper-like” interendothelial junctions
that are commonly found in blood vessels. The cross sectional aspect of the collecting
vessels is regulated by the action of smooth muscle and basal membrane. Collecting
vessels are organized into contractile formations called lymphangions, which are
separated by bileaflet valves that have role in lymph backflow prevention (Bazigou et al.,
2009). The unidirectional lymph propulsion through precollecting and collecting
lymphatics is caused by the concurrent action of the intrinsic contractility of smooth
muscle cells, as well as surrounding skeletal muscles and arterial pulsations (Figure 1).
The lymph accumulated in the afferent collectors is further drained into
subcapsular sinuses of the lymph nodes, fulfilling complex roles in lymph filtration and
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Figure 1. Junctional Organization of LECs. A) Lymphatic capillaries have
discontinuous “button-like” junctions which are characteristic of the oak leaf-shaped
lymphatic endothelial cells. These junctions serve as primary valves to prevent the
backflow of the interstitial fluid from the lymphatic vessels into the tissue. B) Endothelial
cells in collecting lymphatic vessels are elongated and connected by continuous “zipper
like” junctions. C) Functionally, collecting lymphatic vessels are organized in a series of
units, named lymphangions, separated by intraluminal valves. High fluid pressure opens a
valve whereas reverse flow closes the valve ensuring a unidirectional lymph flow.
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storage as well as B and T lymphocytes activation. Lymph nodes are characterized by a
discrete structure encapsulated in connective tissue and they are typically organized in
sequential clusters spread throughout the entire length of the lymphatic system. The
lymph leaves the nodes through efferent collectors that further unite into larger thoracic
ducts which provide the uplink with blood circulation through subclavicular veins.

The lymphatic system simultaneously fulfils a number of key physiological
roles related to the homeostasis of the tissue fluid, immune cell trafficking, and
absorption of dietary fats (Tammela and Alitalo, 2010). To maintain the required tissuefluid homeostatic balance, the terminal vessels of the lymphatic network are involved in a
permanent interstitial absorption of extravasated fluids, macromolecules, lymphocytes
and antigen-presenting cells. The interstitial soluble uptake collected at the capillary
periphery that forms the lymph returns to the bloodstream via larger lymphatics and the
thoracic duct. However, in addition to this conventional passive conduit function, recent
evidence suggests that lymphatic vessels also play a strong and active role in the
modulation of immunity by adjusting the balance between peripheral tolerance and
immunity (Lund & Swartz, 2010). Along its way through the lymphatics, the lymph is
continuously filtered in the nodes in order to initiate immune responses to foreign
particles coupled by antigen-presenting cells (Alitalo et al., 2005). Lymphatics are also
present within the villi of the small intestine in the form of lacteals with a role in the
drainage of long-chain dietary triglycerides and lipophilic compounds released by
enterocytes in the form of chylomicrons (Norrmen et al., 2011 ; Bruyere and Noel, 2010).
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1.2.2

Lymphatic Neogenesis and Associated Markers
Although still a matter of open scientific debate, two distinct terms have been

advanced in the past in conjunction with the formation of lymphatic vessels. Depending
on whether the generation of new lymphatic structures occurs from vascular endothelial
progenitors

or

from

lymphvasculogenesis

pre-existing
or

lymphatics,

lymphangiogenesis,

the

process

respectively.

is
By

called
contrast

either
to

lymphvasculogenesis, which is limited to early embryogenesis, lymphangiogenesis
occurs

both

during

intrauterine

organ

development

and

in

postnatal

life.

Lymphangiogenesis manifests during both normal and healthy processes, as well as under
pathological

conditions

including

malignancies

and

metastatic

dissemination.

Nevertheless, physiological lymphangiogenesis in adults - although rare - exists
especially in context of ovarian growth and wound healing (Paavonen et al., 2000;
Saaristo et al., 2006).
The embryology of lymphatics is tightly interconnected to that of the blood
vasculature, since lymphatics begin to develop by sprouting from jugular veins (Sabin,
1902). The initial development of lymphatics starts with the commitment of the venous
endothelial cells to the lymphatic endothelial lineage in the presence of the transcription
factor Prospero homeobox protein-1 (Prox-1), which also is a commonly used lymphatic
marker. However, the subsequent differentiation and maturation of the lymphatic
vasculature is controlled by additional lineage markers. Among them, the lymphatic
vessel endothelial receptor-1 (LYVE-1) represents the primary indicator of lymphatic
endothelial competence and it is generally regarded as a highly specific marker used to
differentiate between lymphatic and blood vascular endothelia (Jurisic and Detmar, 2009;
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Maby-El Hajjami and Petrova, 2008). Podoplanin is a mucin transmembrane glyco
protein expressed on lymphatic vessel endothelium and with role on its correct function
and formation (Breiteneder-Geleff et al., 1999; Schacht et al., 2003). Finally, positioned
at the core of de novo lymphatics generation is the vascular endothelial growth factor
receptor-3(VEGFR-3) with an active role in the regulation of LEC proliferation,
migration, and sprouting (Jeltsch et al., 1997; Veikkola et al., 2001).

1.2.3

Role of the Lymphatic System in Cancer

1.2.3.1 Lymphovascular Invasion
In contrast to blood vessels, lymphatic vasculature offers a convenient conduit
for invasion and transportation of metastatic cells, since it is natively equipped with celltransport capabilities that support survival and proper activity of the transported cells. As
a result, lymphatics represent a common dissemination pathway for many types of
epithelial tumors, including breast cancer.
Although the actual cellular mechanisms responsible for fluid and cell
transvasation into lymphatics it is still insufficiently understood (Witte et al., 2011), it is
very likely that the increased physiological permeability of the lymphatic to the
interstitial products - caused by the '‘button-like” junctions - also make them easily
penetrable by tumor cells that have already detached from the neighbouring tumoral
mass. Lymphatic vessels are not only easy to invade, but they also provide ideal routes
for migratory tumor cells due to their larger diameters, since even the smallest lymphatic
vessels are larger than blood capillaries. Thus, the combined effect of: i) low
intralymphatic shear stress caused by the reduced flow rate, ii) the absence of mechanic

deformations, and iii) a high lymph concentration of hyaluronic acid, a molecule with cell
protecting properties (Laurent and Fraser, 1992) all tend to significantly enhance the
survival rates of metastatic tumor cells that have managed to escape into lymphatics. As
such, lymphatics are generally regarded as convenient and preferential tumor
dissemination pathways to lymph nodes and beyond (Azzali, 2007).
1.2.3.2

Tumor-Associated Lymphangiogenesis
For

an

extended

period

of time,

the

existence

of tumor-induced

lymphangiogenesis was denied by a large majority of the researchers in the field.
However, after the discovery of lymphatic endothelial markers, this hypothesis began to
be questioned by several studies demonstrating that tumor-induced growth of lymphatic
vessels constitutes in fact one of the active promoters of metastatic dissemination of
primary breast tumors to regional lymph nodes (Padera et ah, 2002; Dadras et ah, 2003).
Despite these findings, the presence of tumor-induced lymphangiogenesis in
breast carcinomas continues to remain uncertain since the strength of somewhat indirect
proofs based on the association of pro-lymphangiogenic markers expression and high
incidence of lymph node metastasis can always be regarded as insufficient (Agarwal, et
ah, 2005; Williams et ah, 2003; Vleugel et ah, 2004; van der Auwera et ah, 2004; van der
Schaft et ah, 2007). Beyond this, it is still unclear whether the lymphatic spread of
mammary tumors occurs through pre-existing or newly-formed lymphatic vasculature
(Ran et ah, 2009).
One of the possible explanations for these seemingly contradictory results
resides in tire partially reduced or even totally absent functionality that was often noticed
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for intratumoral lymphatics (ITL). Indeed, while lymphatics can easily penetrate tumor
stroma and provide a minimal resistance/maximum contact dissemination pathway for
detached cancer cells, their thin-walled conformation makes their lumen more prone to
collapse than blood vessels (Ji, 2006). The increased compression forces exerted on the
walls of ITLs are caused either by the growing tumors (Helmlinger, 1997) or by the
elevated interstitial pressure. Moreover, in addition to the increased compressive
mechanical stress applied on the ITLs by the surrounding environment, several
researchers have linked their reduced/absent functionality to their inherent physiological
abnormal features (Padera et al., 2002; Leu et ah, 2000).
In reality, it seems that tumors might be capable of altering the functions of the
neighbouring pre-existing lymphatic network that will eventually be co-opted into tumor
cell migration with little involvement from endothelial progenitors (He et ah, 2004).The
lymphangiogenic process is known to be controlled by the action of endothelial
extracellular matrix and growth factors (Banerji et ah, 1999; Jackson, 2003). Among
them, tumor-expressed exogenous VEGF-C has been proven to play a decisive role on
LECs development and tumor cell movement, therefore its effect on tumor-induced
lymphangiogenesis and lymph node metastasis is deemed of paramount importance
(Karpenen et ah, 2001; Skobe et ah, 2001; Ji, 2005; Ji, 2006; Timoshenko et ah, 2006;
Matsui et ah, 2008). According to more recent evidence, LECs are capable of extending
filopodia towards the VEGF-C-expressing tumoral mass. These VEGF-driven extensions
will essentially form the future lymphatic vascular sprouts (Alitalo et ah, 2005) that tend
to develop either within or at the periphery of the tumors, as demonstrated in several
experimental tumor models (Saharinen et ah, 2004; Stacker et ah, 2001; Karpanen et ah,

13
2001). In addition to the aforementioned pro-lymphagiogenic factors, macrophages are
also regarded as active players of pathological lymphangiogenesis due to their dual
involvement with both transdifferentiation/direct endothelial incorporation and with the
promotion of pre-existing LECs growth (Kerjaschki, 2005).
However, breast carcinomas might also trigger the lymphangiogenic processes
within the draining nodes. Lymph node metastasis is promoted by a multitude of intricate
factors like: the increased permeability of lymphatics for tumor cells along with their
diminished 'flow rates, the inherent process of tumor-induced lymphangiogenesis, and the
permanent How of the peripherally collected lymph into the sentinel lymph nodes (Das
and Skobe, 2008). Based on these findings, more research studies involving both animal
models and clinical observations have started to acknowledge that lymph node
lymphangiogenesis could be one of the key promoters of the metastatic dissemination of
breast tumor cells at remote sites and/or organs (Kaplan et al„ 2006; Tobler and Detmar,
2006; Hirakawa et ah, 2007; Sleeman et al., 2009). Although it is still unclear how breast
tumors manage to enhance their spreading precisely by the means of lymph nodes
characterized by extremely well defined roles in the immune response, it is believed that
tumor-induced sentinel lymph node lymphangiogenesis could in fact “prepare the
ground” for the upcoming metastatic invasion by promoting a tolerogenic niche
environment (Sleeman and Cremers, 2007).
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1.3

The Lymphangiogenic VEGF-C/VEGFR-3 Signalling Pathway
While the advancements in understanding the role of lymphangiogenesis have

been long delayed by a lack of adequate methodology for identification of its regulatory
molecules as well as for lymphatic endothelium-specific markers (Pepper, 2001; Sleeman
et al., 2001), their discovery at the end of the 1990s practically opened a new area in
cancer research. In the past few years, it has became clear that intratumoral, peritumoral
and even sentinel node formation of new lymphatics is ultimately controlled by a
complex network of growth factors. Most of the techniques that are currently available to
demonstrate the presence of lymphangiogenesis rely on the detection of lymphatic
endothelial (LYVE-1, podoplanin, Prox-1, VEGFR-3) markers, as well as on an increase
in lymphatic vessel density (Ran, 2009).
Once the initial problems associated with the positive identification of
lymphangiogenesis were solved, two new questions arose: 1) what is the inherent
mechanism responsible for the induction of lymphangiogenesis; and 2) what exactly
makes the tumor cells leave the tumoral mass and enter lymphatics. In this sense, recent
evidence suggests that one of the possible answers to both questions resides in the
crosstalk between VEGF-C and chemokines. However, an absolute consensus has not
been reached yet.
When it comes to the first question formulated above, the most investigated and
best characterized signal-transduction pathway involved in lymphatic endothelial cell
proliferation, migration, and survival is represented by VEGF-C and its cognate receptor
VEGFR-3 (Alitalo, 2005; Thiele and Sleeman, 2006; Su et al., 2007; Da et al., 2008).
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VEGFR-3, also known as FLT-4, is a tyrosine kinase receptor expressed during
early embryonic development both by venous and lymphatic endothelium. Nevertheless,
in the postnatal life, VEGFR-3 is predominantly expressed on the surface of lymphatic
endothelial cells, as well as by monocytes, macrophages, and dendritic cells (Hamrah et
al., 2003, Schoppmann et ah, 2002). However, during pathological lymphangiogenesis,
VEGFR-3 is expressed by the capillary endothelium of tumor tissues (Laakkonen et ah,
2007).
Structurally, VEGFR-3 consists of an extracellular ligand-binding region
composed of six immunoglobulin-like domains, a single transmembrane domain, and an
intracellular conserved tyrosine kinase domain followed by a C-terminal tail (Pajusola et
ah, 1994; Ran et ah, 2009; Nilsson et ah, 2010). The tyrosine kinase receptor VEGFR-3
is present in two alternatively spliced isoforms, long and short, which differ in their Cterminal ends, and also have different signalling capabilities. The short splice variant is
predominantly expressed in breast carcinoma and frequently correlates with lymphatic
metastasis (Gunningham et ah, 2000; Hughes et ah, 2010). VEGFR-3 exists as an
inactive monomeric protein in an unbound state. Upon binding of the proteolytically
processed form of VEGF-C, VEGFR-3 can form homodimers or heterodimers (with
VEGFR-2) leading to the activation of a special combinatorial signalling pathway
(Olsson et ah, 2006).
VEGF-C is a member of the VEGF family of growth factors, which are highly
conserved
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(Pepper, 2001). Observation of animal models has revealed that VEGF-C is an important
regulator of lymphangiogenesis since VEGF-C-knockout mice fail to form primary
lymphatic sprouts, lack all lymphatic vessels, and die before birth (He et al., 2004).
VEGF-C is secreted as a full-length inactive form consisting of NH2 - and
COOH- terminal pro-peptides. After proteolytic cleavage, mature dimers bind and
activate the VEGFR-3 receptor that - through tightly regulated pathways - controls the
activation and sprouting of the lymphatic endothelial cells. VEGF-C is expressed in
malignant, tumor infiltrating and stroma cells and creates an adequate tumor environment
for generation of new lymphatic vessels (Figure 2). Also, VEGF-C qualitatively
modulates the lymphatic vasculature to promote tumor metastasis. VEGF-C stimulates
the formation of specialized intercellular gaps which in turn facilitates tumor entry into
lymphatics (Tammela et al., 2007). VEGF-C also plays an active role in widening and
enlarging the collecting lymphatic vessels that translates into: i) an increased lymph flow
from the immediate tumor environment; ii) transportation of tumor cells; and iii)
accommodation of larger tumor aggregates (He et al., 2005; Alitalo et al., 2005). The
increased lymph drainage could activate the immunotolerant functions of lymph nodes
through the upregulation of suppressor molecule expression as well as through an
increased exposure of the lymph node to lymph-transported tumor antigens (Lund &
Swartz, 2010).
Tumor derived VEGF-C can also attract macrophages and upregulate the
expression of the CCL21 chemokine to further alter the tumor microenvironment and
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promote lymphatic invasion. Moreover, VEGF-C and CCL21 seem to be characterized
by a significant crosstalk which opens the door to an interesting avenue proposing that
VEGF-C might be the root cause of the immunogenic to tolerogenic switch noticed in
tumor microenvironment (Lund & Swartz, 2010). Several recent studies have shown that
both VEGF-C and VEGFR-3 are in fact expressed by tumor cells, suggesting that they
promote tumor cell proliferation and invasiveness through autocrine mechanisms (Ueda
et al., 2001; Su et al., 2006; Timoshenko et ah, 2007; Issa et ah, 2009).
Communication pathways at the “tumor-vessel interface” are able to guide
sprouting lymphatic microvessels toward tumors and instruct tumor cells to spread to
distant sites. Recent evidence suggests that these events are orchestrated, at least in part,
by the interplay between vascular endothelial growth factors and chemokines.

1.4

Chemokines

1.4.1

Structure and Signal Transduction
Chemokines are defined as a large cytokine family of small molecular weight

proteins (8-14 kDa). More than 50 chemokines have been identified so far, and there are
at least 22 receptors associated with them (Balkwill, 2004; Barbieri et ah, 2010; Lazennec
and Richmond, 2010). A summary comparison of these two numbers suggests that the
chemokine world is characterized by redundant signalling since chemokines and their
receptors have overlapping specificities. This practically means that multiple chemokines
bind to more than one receptor and many of the chemokine receptors interact with more
than one chemokine (Figure 3; after Lazennec and Richmond, 2010). Despite the lack of
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Figure 3. Ligand-Binding Patterns of the Chemokine Families. Chemokines are
characterized by redundant signalling. Most chemokines bind to more than one receptor
and a single receptor can interact with multiple chemokines. This situation is typical for
most of the CC (blue) and CXC (green) chemokine families. By contrast, some
chemokine receptors (red) bind only one ligand. Decoy receptors (yellow) can bind
multiple chemokines but act as “deceptors” since they do not signal.
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chemokine affinity for a unique receptor, each chemokine pair is characterized by
distinctive functions (Devalaraja and Richmond, 1999; Murphy et al., 2000; Zlotnik et
al., 2006; Hembruff and Cheng, 2009).
Chemokine taxonomy is typically performed according to structural and
functional criteria. From a structural perspective, the behaviour of the chemokines - in
terms of the

leukocyte population targeted or their involvement in various

physiopathological processes - is influenced to a large extent by the specific sequence of
conserved cysteine residues that is present within the chemokine molecule. Structurally,
chemokines are characterized by a conserved protein structure scaffold with two
conserved disulfide bonds connecting cysteine residues. These are located in the
proximity to the amino-terminus and further closer to the carboxyl-terminus of the
protein. Based on the positioning of the two conserved cysteine residues near their
amino-terminus, chemokines are classified into subfamilies/groups called C, CC, CXC,
CX3C. While the two conserved cysteine motifs in the CC group are adjacent to each
other, there is an additional amino acid between these two cysteins in the CXC group,
with X denoting the number of amino acid residues (Figure 4). Taken together, CC and
CXC are, by far, the largest and the most studied groups of chemokines.
From a functional standpoint, chemokines can be grouped into homeostatic and
inflammatory types, depending on their origin and the tasks performed. Homeostatic
chemokines are expressed in lymphoid organs with a role in homeostatic trafficking of
leukocytes, while inflammatory chemokines are produced in response to inflammation
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Figure 4. Schematic Representation of the Chemokine Classes. The structure of the
chemokines encloses two conserved disulfide bonds connecting cysteine residues that are
positioned in the vicinity of the amino-terminus and carboxyl-terminus. The position of
the cysteins in the amino-terminus part of the chemokines defines each chemokine class.
In the CC group, the first two cysteins are proximal to each other, while in the CXC and
CX3C groups there are one and three amino acids between them, respectively.
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and immune stimuli (Baggiolini et al., 1997; Mantovani 1999; Murphy et al., 2000;
Zlotnik and Yoshie, 2000; Locati et al., 2002; Rot and von Andrian, 2004; Raman et al.,
2011; Mantovani et al., 2010).

Chemokines elicit cellular responses by binding to their cognate seven
transmembrane domain G protein-coupled receptors (GPCR). Chemokine receptors
function as allosteric molecular relays where the chemokines signal to the extracellular N
terminus domain, leading to phosphorylation at the C-terminus, and allowing the
activation of the heterotrimeric G protein complex, bound to the intracellular domain of
the receptor. Activation involves the separation of the Ga from GPy subunits and then
subsequent activation of their downstream effectors (Neptune and Bourne, 1997; Raman
et al., 2011). In addition, chemokine receptors can undergo constitutive homo or hetero
dimerizations leading to crosstalk between various receptors, concomitant with
significant physiological consequences. For instance, the heterologous transactivation of
the epidermal growth factor receptor, a tyrosine kinase receptor, by an activated
chemokine GPCR has been shown to promote cancer cell proliferation (Porcile et al.,
2004; Porcile et al., 2005).
The chemokine system is also characterized by a distinct subset of silent
chemokine receptors that are specialized in chemokine sequestration, and therefore
control chemokine bioavailability. These receptors do not elicit conventional signalling
and modulate cellular responses through signalling-competent receptors (Peiper et al.,
1995; Gosling et al., 2000; Locati et al., 2005; Mantovani et al., 2006; Comerford et al.,
2007). Several studies have shown that the decreased expression of decoy receptors
correlates with lymph node metastasis and decreased survival rates in breast cancer. Their
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expression controls the amount of intratumoral chemokines, and therefore modulates
immune responses, vessel density, and tumorigenesis (Wu et al., 2008; Feng et al., 2009;
Raman et al., 2011).
Chemokines trigger a variety of effector pathways after binding to their specific
G protein coupled receptors. Signalling through phosphatidylinositol 3-kinase (PI3K) and
its downstream mediator protein kinase B (AKT) promotes cancer cell survival,
migration, and invasion (Barbero et al., 2003). Besides survival, chemokines activate the
mitogen activated-protein kinase (MAPK) cascade, and Rho family of GTPases that are
responsible for tumor growth (Fang and Hwang, 2009; Barbiéri et al., 2010). Chemokine
receptors also activate signalling pathways independent of G proteins, including
p38MAPK (Goda et al., 2006) and JAK/Stat (Vila-Coro et al., 1999), to regulate cellular
processes such as migration and gene transcription (Hembruff and Cheng, 2009).

1.4.2

The Role of Chemokine Signalling
Under physiological conditions, chemokines and their receptors are generally

regarded as key mediators of cellular recruitment with strong consequences on both
native and adaptive immune responses. Chemokines communicate with their target
immune effectors through their G-protein coupled receptors and are capable of
modulating the influx of certain leukocyte populations, depending on the specific needs
of the afflicted tissue. Chemokines are secreted at the site of inflammation thereby
becoming veritable homing beacons for the chemotaxis of immune cells guided by the
chemokine concentration gradients (Dubinett et al., 2010).
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While the chemotactic role of the chemokines in inflammation caused by injury
or infection is probably the most acknowledged one, these molecules are in fact involved
in many other physiological processes concerning lymphoid tissue ontogenesis,
organogenesis, vasculogenesis and tissue repair (Garin and Proudfoot, 2011). The wide
plethora of roles played by chemokines is generally regarded as a direct result of their
significant regulatory effects, exerted on migration, proliferation and survival signals in
multiple cell types (Hembruff and Cheng, 2009).
The physiological expression of chemokines is controlled by an extremely fine
tuned system, whose delicate balance cannot be broken without significant implications
on the well being of the entire human organism. On one hand, a subverted expression of
the chemokines often intertwines with the pathobiology of chronic inflammation. On the
other hand, the uncontrolled amplification of chemokine expression represents one of the
primary causes of autoimmune diseases whose pathology is sometimes manifested in
conjunction with tumor development. As such, taking advantage of the highly conserved
chemokine expression between humans and mice, the physiological functionalities of the
chemokines were thoroughly explored in both in vivo and in vitro studies (DeVries et al.,
2006; Zlotnik et al., 2006).
1.4.3
1.4.3.1

The Role of Chemokines in Cancer
Expression Pattern in Cancer
Among many other functions, normal breast tissue is capable of expressing a

broad panel of chemokines, typically belonging to the CXC and CC classes. However,
their physiological levels, measured in human milk (Maheshwari et al., 2003) or primary
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cultures of normal breast epithelial cells from healthy patients (Basolo et al., 1993) are
extremely low.
Numerous studies have indicated that chemokine patterns change drastically
after the onset of tumoral activity in mammary tissues. According to the most commonly
accepted theory, the malignant switch in breast epithelial cells is responsible for a
considerable up regulation in chemokine levels (Ali and Lazennec, 2007). By contrast,
serial analysis of gene expression (SAGE) suggested that some of the chemokineregulating genes that were highly expressed in normal breast epithelium were in fact lost
during normal-to-carcinoma transition, while others were upregulated (Porter et ah,
2001). Regardless of the case, these evident phenotypic changes could be exploited in the
future for targeted therapy.
Extensive immunohistochemistry and RNA in situ analyses have revealed that
an elevated expression of certain members of the chemokine family and their cognate
receptors correlates reasonably well with poor prognosis, as well as with lymph node
metastases in cancer patients (Hembruff and Cheng, 2009). Indeed, the epithelial-specific
expression of chemokines and their receptors has been established at protein and RNA
levels in breast cancer, and in many other types of malignancies (Wente et ah, 2008).
Interestingly, the upregulation of the chemokines in breast cancer is generally associated
with the downregulation of the decoy receptors (Wu et ah, 2008), which may imply that
tumor cells are characterized by intense chemokine signalling activities.
When it comes to the identification of the specific chemokine molecules that are
upregulated in breast carcinomas, without exhibiting an absolute consensus, the surveyed
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literature seems to imply that CXCL8, CXCL12, CCL2, CCL4 and CCL5 are some of the
most studied members of the chemokine class (Ali and Lazennec, 2007). Sometimes the
studies performed on a particular member of the chemokine family were extensive to
justify a certain “role model” status, often attributed to the CXCL12/CXCR4 chemokine
pair due to its involvement in both sentinel lymph node and remote metastasis associated
with mammary tumors (Ben-Baruch, 2008). It is extremely important to point out that the
expression of a certain chemokine receptor does not automatically translate into its
functionality with respect to its ligand. CXCR4 is a classic example in this sense, since it
has a relatively uniform expression in several breast cancer cell lines as measured
through Western Blot, flow cytometry or ligand binding, but its signalling capabilities
have only been detected in metastatic cell lines (Holland et al., 2006). The elevated levels
of these chemokines was associated with elevated levels of tumor-associated
macrophages (Ueno et ah, 2000) and it was later found that not only tumor cells, but also
tumor stroma could be a source for chemokine production (Finak et ah, 2008).
However, when it comes to the particularities of breast tumors, newer research
studies suggest a broadened palette of chemokine involvement. The enlarged spectrum
now includes less investigated members of the CC chemokine class, among which the
CCL21/CCR7 pair is presently believed to play a role that is at least of equal significance
with CXCL12/CXCR4. When compared to normal breast tissue, CCR7 was found to be
upregulated in primary tumors, in particular to human invasive lobular and ductal
carcinomas (Cabioglu et ah, 2005b; Andre et ah, 2006). CCL21, the ligand binding to
CCR7, is physiologically present in lymph nodes, but its expression was found to be
considerably increased in lymph node-positive versus lymph-node negative breast cancer
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patients (Wilson et al., 2006). Taken together, these findings provide a foundation for the
lymph node selectivity of mammary tumor cells and reinforce once more that the normal
to tumoral switch in breast tissue is associated with a dramatic change in chemokine
pattern expression.
1.4.3.2

Regulation o f Chemokine Expression
Since there is no doubt that tumor development is linked to changes in

chemokine expression, intensive efforts are currently directed towards identifying the
inherent mechanisms responsible for these alterations. When it comes to chemokine
expression in epithelial and mesenchymal cells, specific environmental and soluble
factors are often cited as major players involved in their upregulation. Among them,
hypoxia-related and/or numerous growth factors (HGF, EGF, TNF-a, IL-6, LMP1) were
shown to contribute decisively to the regulation of chemokines and their cognate
receptors in both epithelial and endothelial cells (Matteucci et al., 2007; Maroni, et al.,
2007; Buettner et al., 2007; Kulbe et al., 2005). Notable results along this direction were
obtained, for example, through the correlations established in context of breast tumors
between IL-lß/TNFa and CCL2 (Freund et al., 2004), EGF and CXCL8 (Azenshtein et
al., 2005). The most acceptable explanation proposed for this correlative expression
resides in the commonality of the signalling pathways involved both in the upregulation
of chemokines and that of the aforementioned proteins (Shim et al., 2006).
Other important connections have been made between the expression of
tyrosine kinase receptors with well-defined roles in mammary malignancy and
chemokines. The functional links already established between CXCR4 and HER2 (Li et
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al., 2004; Cabioglu et al., 2005a), and IGF-1R (Akekawatchai et al., 2005), might mean
that at least some of the tumor promoting factors are also active players in the regulation
of chemokine expression.
Finally, in addition to the mechanisms outlined above, the most recent
evidences seem to suggest that genetic mutations are also accountable for chemokine
expression abnormalities (Hembruff and Cheng, 2009). Chemokines constitute direct
targets of several oncogenes involved in the pathogenesis of a broad range of human
tumors. The genetic lesions caused by these oncogenes are responsible for the
upregulation of the chemokines that in turn induce the activation of an entire
inflammatory cascade (Allavena et al., 2011). To illustrate this concept, for instance,
CCR7 has been proved to be upregulated by the p53 mutation in T cell-acute lymphocytic
leukemia as a result of the activation of the Notch 1 signalling pathway (Buonamici et al.,
2009). However, the surveyed literature presents numerous other examples connecting
chemokines and their receptors with various other oncogenes like mutant p53, Ras, and
Myc as well as with the deregulation of the transcriptional factors involved in chemokine
transactivation (Mantovani et al., 2010).
1.4.3.3

Chemokine Signalling in Cancer Progression
Chemokines are one of the key players involved in tumor progression since

many of the multiple pathways involved in tumorigenesis, including primary tumor
growth, leukocyte recruitment, angiogenesis, survival, and metastasis rely on chemokines
to fulfil their functions. However, prior studies seem to suggest that they might be
responsible for antithetical roles, since in some situations the presence of chemokines is
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vital for tumor progression, while in other cases chemokines become veritable drivers of
anti-tumor defence. The actual role played by certain chemokines in malignancy
generally depends on their type and on microenvironmental characteristics. Evidently, the
balance between pro- and anti-tumor chemokines has a major impact on tumor
development (Balkwill and Mantovani, 2001; Huang et al., 2002; Raman et al., 2007;
Garin and Proudfoot, 2010).
The presence of certain chemokines in the tumor microenvironment enables
tumor cells to acquire the essential characteristics required for malignant growth: self
renewal, activation of anti-apoptotic pathways, unlimited replicative potential, sustained
angiogenesis, and acquisition of an invasive phenotype (Hanahan et al., 2000).
With respect to the angiogenic effect of chemokines, it has been established that
several members of this family can mediate angiogenesis directly through the activation
of matrix metalloproteases, as well as the stimulation of endothelial cells migration and
proliferation (Giraudo et al., 2004; Ma et al., 2007). In addition to the aforementioned
mechanism, some chemokines can indirectly mediate angiogenesis through the
recruitment of leukocytes and subsequent production of vascular endothelial growth
factors (Mantovani et al., 2006; Lewis et al., 2006; Sozzani et al., 2007). Furthermore,
chemokines were found to be active mediators in the recruiting of vascular smooth
muscle cells toward endothelial cells. They are also capable of regulating the angiogenic
switch that in turn will provide the tumor cells with essential nutrients and oxygen (BenBaruch, 2006; Strieter et al., 2006; Mehrad et al., 2007; Keeley et al., 2008; Waugh and
Wilson, 2008; Mishra et al., 2010).
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Analogous to their physiological role in the regulation of cell trafficking, one of
the first identified cancer-related effects of chemokines was related to their participation
in tumor cell migration and organ selective metastasis (Ben-Baruch, 2008). A plethora of
studies has indicated that the selective, non-random distribution of tumor cells to remote
tissues in a chemokine-dependent manner relies on the perfect match between
chemokines and their cognate receptors according to “seed and soil” theory developed by
Paget (1889) and reviewed by Ribatti et al. (2006). Due to their chemokine expressing
capabilities, various body organs become veritable metastatic targets since they attract the
chemokine receptors expressed by tumor cells. Also, it was found that tumor cells tend to
increase their adhesiveness and invasiveness under the action of chemokines released by
remote organs, partly due to the activation of focal adhesion kinase and the actin
polymerization signalling pathway (Lee et al., 2004; Prasad et al., 2004; Fernandis et al.,
2004; Ben-Baruch, 2008).
1.4.4

CCL21/CCR7 Axis

1.4.4.1

Expression Pattern of the CCL21/CCR7 Pair
Like other chemokines, CCL21

and its cognate receptor CCR7 are

physiologically involved in the control of leukocyte trafficking to secondary lymphoid
organs (peripheral lymph nodes). However, in addition to the well acknowledged roles of
CCL21/CCR7 pair in chemotactic guidance and in the adhesion of circulating leukocytes
to the vascular endothelium of high endothelial venules, more recent studies also
emphasize their involvement in cytoarchitecture and the maturation of leukocytes
(Sanchez-Sanchez et al., 2006).
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The two major leukocyte subsets whose surfaces express CCR7 are dendritic
and T cells, but there is an important distinction between them: while naive T cells
express CCR7 constitutively in order to allow their continuous recirculation through
secondary lymph nodes (Forster et al., 1999), the surface of dendritic cells begins to
express CCR7 only after tissue injury or cytokine-induced activation (Saeki et ah, 1999).
This behaviour suggests that CCR7 has a strong implication in both central and
peripheral tolerance (Worbs and Forster, 2007). On the other hand, CCL21 is
constitutively expressed by the lymphatic endothelium of multiple organs, high
endothelial venules of lymph nodes and Peyer’s patches, as well as stromal cells in T cell
rich areas of lymph nodes, spleen and Peyer’s patches (Fang and Hwang, 2009). The
wide physiological distribution, combined with the complex and multifaceted roles in
lymph node trafficking is probably what makes the CCL21 chemokine and its cognate
receptor an extremely suitable candidate for the fast dissemination of the breast cancer
cells developed in immediate proximity of the lymphatics. Following the discovery by
Muller et al. (2001) that a number of the chemokine receptors - including CCR7 - are
upregulated in a distinct and non-random pattern in breast cancer, and that CCL21 is
abundantly expressed by lymph nodes, the involvement of CCL21/CCR7 chemokine pair
in mammary malignancies became more than a simple speculative theory. Subsequent
research studies have demonstrated that the overexpression of CCR7 correlates well with
enhanced lymph node metastasis in animal models (Pan et al., 2009; Cunningham et al.,
2010). CCR7 upregulation in human cancer correlates with tumor size, increased
incidence of lymph node metastasis, and poor survival rates (Andre et al., 2009; Liu et
al., 2010). Interestingly, the CCR7-expressing breast cancer cells are capable of secreting
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CCL21 in an autocrine manner, especially in 3D environments (Shields et al., 2007),
demonstrating the importance of the microenvironment on chemokine signalling.
1.4.4.2

Mechanisms that Promote CCR7 Upregulation
Despite the unambiguous correlation between CCR7 upregulation and the poor

outcome of breast carcinomas, the mechanisms underlying CCR7 expression by tumor
cells continue to remain relatively obscure (Forster et al., 2008). One of the possible
mechanisms suggested for an increase in CCR7 expression by tumor cells is epigenetic
changes, such as deacetylation and DNA methylation (Mori et al., 2005). Another
potential factor responsible for CCR7 upregulation in breast cancer cells is
cyclooxygenase-2 (COX-2) mediated prostaglandin E2 (PGE2) production. COX-2 was
shown to upregulate CCR7 expression via E-prostanoid receptors (EP2, EP4) in breast
cancer cells (Pan et al., 2008).
Other studies have revealed that CCR7 upregulation at both the mRNA and
protein levels could also be caused by the overexpression of endothelin receptors (Wilson
et al., 2006). Since the expression of the endothelins and their receptors in breast cancer
cells is induced by hypoxic conditions and inflammatory cytokines (Grimshaw, 2005), it
can be inferred that local factors present within the tumor microenvironment might play a
determinant role on CCR7 upregulation.
1.4.4.3

CCR7 and G Proteins Signalling
Similar to all other chemokine receptors, CCR7 belongs to the family of seven

transmembrane domain heterotrimeric G protein-coupled receptors (GPCR). A cascade of
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downstream intracellular events is triggered by CCR7 activation by its CCL21 ligand
(Rubin et al., 2009). The immediate consequence of the binding between CCR7 and its
CCL21 ligand is constituted by the phosphorylation and activation of the downstream G
protein complex, adjacent to this receptor (Arai and Charo, 1996; Kuang et al., 1996).
Following activation, G proteins associate with their effectors and further propagate the
intracellular signals.
However, it is important to note that G protein activation is accompanied by a
dissociative process that separates the Got and GPy subunits. The two distinct subunits
yielded after separation play distinct roles on the intracellular signalling scene. On one
hand, the G(3y subunit interacts with p 101, a protein associated with the pi 10 catalytic
subunit of PI3K and thereby induces signalling through PI3K (Stephens et al., 1994) and
its downstream mediator AKT. Given the well established role of the PI3K/AKT pathway
on protection from cellular apoptosis (Datta et al., 1999), it is easy to assert that
activation of P13K following CCL21/CCR7 binding is one of the multiple mechanisms
invoked by breast cancer cells in order to survive the attack of the immune system (Fang
and Hwang, 2009). An analogous premise has already been validated for CCR7
signalling in the context of dendritic and effector CD8+ T cells (Sanchez-Sanchez et al.,
2004; Kim et al., 2005). Although investigated considerably less so far, the Got subunit
released after G protein activation following CCL21/CCR7 binding activates the
mitogen-activated protein kinase (MAPK) signalling cascade, with established impact on
tumor cell proliferation, invasiveness, and migration
(Figure 5).

(Redondo-Munoz et al., 2008)
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Figure 5. Schematic of the CCR7 Signalling Pathways. Upon CCR7 chemokine
receptor activation by CCL21 stimulation, the G-protein complex dissociates and triggers
different signal cascades. GPy subunits activate phosphatidylinositol 3 kinase (PI3K) and
phospholipase C (PLC) whereas the Got subunit activates mitogen-activated protein
kinase (MAPK)/extracellular regulated kinase (ERK) pathway. Protein kinase B (AKT) is
activated downstream of PI3K and is mainly responsible for cell survival.
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1.4.4.4

The Role o f CCL21/CCR7 Axis in Breast Cancer
The CCL21/CCR7 pair has several different grades of involvement in the

growth and dissemination of human tumors. While the complete picture of CCL21/CCR7
participation in breast cancer is still unclear, some of its primary roles have already been
outlined reasonably well in recent years and they will be detailed below.

The particularities of the physiological functions fulfilled by CCL21/CCR7
make this pair of chemokines an ideal candidate for the metastatic dissemination of tumor
cells, essentially by exploiting their lymph node chemotactic/trafficking properties.
Animal studies indicate that metastatic tumor formation is decreased when CCL21
expression is knocked down in secondary lymphoid organs, since this diminishes both the
chemotactic and anti-apoptotic effects in CCR7-expressing tumor cells (Wang et al.,
2008). By contrast, CCR7 positive tumors grow more rapidly in the presence of CCL21
ligand, both in vivo and in vitro cultures ( Takeuchi et ah, 2004; Wang et ah, 2005; Sun et
ah, 2009; Cunningham et ah, 2010). Furthermore, CCR7 expression leads to increased
pi-integrin-mediated tumor growth and hence promotes tumor migration to the lymph
nodes (Cunningham et ah, 2010). In addition, it has been found that CCR7 prevents
anoikis by regulating detachment-induced apoptosis in metastatic breast cancer cells
(Kochetkova et ah, 2009).
Many members of the CC chemokine family were found to play active roles in
tumor dissemination to specific tissues throughout the body, such as the skin, gut and
liver (Lazennec and Richmond, 2010). When it comes to the specifics of CCL21
involvement in chemotactic signalling, researchers have shown that the CCL21/CCR7
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pair plays a prominent role in the metastatic dissemination of breast tumor cells to lymph
nodes (Muller et al., 2001; Cabioglu et al., 2005b; Cabioglu et al., 2007; Cunningham et
al., 2010). Moreover, a recent study revealed that in addition to lymph node metastasis,
this pair also mediates brain infiltration by T-cell acute lymphoblastic leukemia
(Buonamici et al., 2009).
Furthermore, analogous to the physiological contribution of this pair to
leukocyte maturation and cytoarchitecture, CCR7 activation by its CCL21 ligand is also
responsible for rapid intracellular actin polymerization/cytoskeleton reorganization,
followed by the formation of pseudopodia, which dramatically enhances the motility and
invasiveness of human breast cancer cells as well as other types of tumor cells (Muller et
al., 2001; Ding et al., 2003; Sancho et al., 2006; Wang et al., 2005).
Among various roles played by the CCL21/CCR7 pair in breast cancer, perhaps
the one related to migration and guidance of the cells detached from the primary tumor
towards draining lymphatics has a crucial role on the subsequent metastatic evolution of
the disease. Questions remain as to whether there is any link between the CCL21/CCR7
axis with the lymphangiogenic factors VEGF-C and VEGF-D. Evidently, the autocrine
secretion of VEGF-C and D by tumor cells facilitates tumor cell dissemination, since
these growth factors favour intra/peritumoral lymphatic development. As such, since
primary tumors are capable of creating their future propagation pathways, these events
may explain why the overexpression of VEGF-C and D in the experimental tumor
models leads to enhanced metastasis to lymph nodes (Skobe et al., 2001; Mandriota et al.,
2001; Stacker et al., 2001; He et al., 2005).
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However, while all these observations constitute rather indirect proofs of the
crosstalk between VEGF-C and CCL21, new evidence has demonstrated that the
interplay between these two molecules influences breast cancer progression by multiple
distinct, but complementary mechanisms (Shields et al., 2007; Issa et al., 2009):
i)

The autocrine secretion of VEGF-C by tumor cells increases tumor invasiveness
by increasing the proteolytic activity and motility of tumor cells.

ii)

VEGF-C also acts in a paracrine manner to increase the lymphatic endothelial
secretion of CCL21.

iii)

The autocrine secretion of CCL21 by tumor cells guides the transcellular
migration of CCR7-expressing tumor cells under the slow interstitial flow.

iv)

Once the tumor cells have departed from the matrix, the paracrine secretion of
CCL21 takes over and guides the CCR7-expressing tumor cells towards
draining lymphatics.
Taken together, these observations - essentially built around the paracrine and

autocrine mechanisms associated with VEGF-C and CCL21 - point out that the synergy
between these two axes is a major factor in the metastatic propagation of breast tumors.
One of the newest established roles of the CCL21/CCR7 pair is related to its
lymphangiogenic potential. In the tested mouse models, CCR7 expression correlated well
with lymphatic vessel density and lymph node metastasis, therefore having a major
impact on proliferation and invasiveness of colon cancer (Yu et al., 2008). Another study
has concluded that the interaction between CCL21 chemokine and its cognate receptor
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constitute a critical event in progression of pancreatic cancer due to the induction of the
lymphangiogenic process (Zhao et al., 2011).
Perhaps the most intriguing role of CCL21/CCR7 in tumor dissemination is
related to its modulatory effects on the tumor microenvironment. According to a recent
study, Shields et al. (2010) showed that CCL21 -secreting tumor cells are responsible for
a tolerogenic switch in the host’s immune response. Consistent with prior findings which
emphasize that the lymph node stroma plays a major role in promoting tolerance to self
antigens, it was found that CCL21 -expressing tumors are capable of evading immune
surveillance by developing stromal zones reminiscent of lymph node paracortex stroma.
The intrinsic mechanism of the tolerogenic switch in the microenvironment induced by
CCL21-expressing tumors relies on regulatory shifts in T cell populations. As an overall
result, the CCL21 overexpressing tumors grew significantly larger when implanted in
immunosuppressed mice, reinforcing the effectiveness of CCL21/CCR7 signalling on the
promotion of immune tolerance to tumors.

1.5

Rationale
The chemokine ligand/receptor CCL21/CCR7 pair plays a significant role in

tumorigenesis and in the migration of tumor cells into the sentinel lymph nodes in
mammary malignancies. In fact, CCR7 receptor has emerged as an important marker in
the prediction of axillary lymph node metastasis in breast cancers, since CCR7
expression correlates with larger primary tumors, and deeper lymphatic invasion.
In human breast cancer cell lines, the epithelial expression of CCR7 chemokine
receptor has been validated both at the mRNA and protein levels (Muller et al., 2001).
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Several studies have shown that a number of different CCR7 positive tumor cell lines can
create themselves a gradient of CCL21 chemokine, which increases under the slow
interstitial fluid flow towards draining lymphatics (Shields et al., 2007; Shields et al.,
2010). Additionally, CCL21 secretion by endothelial cells has been reported to be
upregulated by the lymphangiogenic factor, VEGF-C (Issa et al., 2009).
The crosstalk between vascular growth factors and chemokines is now believed
to play an important role in tumorigenesis (Barbieri et al., 2010) and in this regard, the
existence of a novel link between CCL21 chemokine and VEGF-C has been recently
uncovered. Moreover, it seems that CCL21 and VEGF-C act synergistically in the
process of invasion (Issa et al., 2009; Cohen-Kaplan et al., 2008; Yu et al., 2007).
Another link was established between COX-2/VEGF-C and CCR7 chemokine
receptor. Studies from our laboratory reported that COX-2 expression by breast cancer
cells plays a key role in VEGF-C secretion via the EP1/EP4 receptor by endogenous
PGE2 (Timoshenko et al., 2006). Subsequently, Pan et al. (2008) established that COX-2
increased CCR7 expression via the EP2/EP4 receptor, suggesting that CCR7 is a
downstream target for COX-2 to enhance migration of breast cancer cells and to promote
lymphatic invasion. However, they did not verify whether CCR7 plays any role in
VEGF-C production by breast cancer cells.
New reports have also suggested the involvement of CCL21/CCR7 pair in
lymphangiogenesis (Yu et al., 2008; Zhao et al., 2011). Since the latest data published on
this topic concluded that the activation of CCR7 signalling constitutes a critical event in
the progression of pancreatic cancer, due to the induction of the lymphangiogenic
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process, it is very likely that a similar mechanism is also present in mammary
carcinomas. Moreover, due to its ability to induce migration and proliferation, the
CCL21/CCR7 chemokine axis is an ideal candidate for the lymphangiogenic spread.

1.6

Hypothesis and Objectives
Based on the foregoing findings, the present study proposes that activation o f

CCR7 signalling is responsible fo r upregulation o f VEGF-C secretion associated with
breast cancer-induced lymphangiogenesis (Figure 6).
The proposed hypothesis will be tested through the following objectives:
1.

To determine whether CCR7 expression plays a regulatory role in VEGF-C
secretion by breast cancer cells.

2.

To identify the underlying molecular mechanism of CCL21/CCR7-induced
VEGF-C secretion by breast cancer cells.

3.

To test the lymphangiogenic potential of CCL21/CCR7 chemokine pair in vitro.
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Figure 6. Hypothesis. Activation of CCR7 signalling is responsible for up regulation of
VEGF-C secretion associated with breast cancer-induced lymphangiogenesis.
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2.1

Materials
BD Falcon cell culture flasks (75 cm ), 6-well plates, 96-well plates, Transwell
inserts (24-well plate, 6.5 mm diameter, 8 pm pore size), BD Cell Recovery
Solution (cat. #354253), and Growth Factor Reduced (GFR) Matrigel (cat.
#356231) were from BD Biosciences, CA.
Corning Ultra-Low Attachment 6-well plates (cat. #3473) were purchased from
Cole-Parmer, IL.

RPMI 1640 Medium (cat. #224000), DMEM Medium (cat. # 12634), Fetal
Bovine Serum (FBS) (cat. #12483), Dulbecco’s Phosphate-Buffered Saline
(DPBS)

(cat.

#14190),

0.25%

Trypsin-EDTA

(cat.

#325200),

Penicillin/Streptomycin (cat. #15140), Platinum® PCR SuperMix High Fidelity
(cat. #12532-016) were purchased from Invitrogen, GIBCO, ON.
M-PER® Mammalian Protein Extraction Reagent (cat. #78501), HALT™
Protease Inhibitor Cocktail (cat. #PI78410), BCA™ Protein Assays kit (cat. #
23225), DAPI (4’, 6-diamidino-2-phenylindole, dihydrochloride) (cat. # 46190)
were from Thermo Scientific, IL.
Phosphatase Inhibitor Cocktail 2 (cat. #P5726), Phosphatase Inhibitor Cocktail
3 (cat. #P0044), and Albumin from Bovine Serum (BSA) (cat. #030M1610)
were from Sigma-Aldrich®, MO.
Recombinant human CCL21/6 Ckine (cat. #366-6C), mouse monoclonal anti
human CCR7 antibody (cat. #MAB197), goat anti-human 6 Ckine antibody (cat.
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#AF366), mouse IgGl isotope control-PE (cat. #IC002P), anti-human CCR7
phycoerythin conjugated mouse IgG (cat. #FAB197P), Quantikine® Fluman
CCL21/6Ckine Immunoassay (cat. #D6C00), and Quantikine® Human VEGF-C
Immunoassay (cat. #DVEC00) were acquired from R&D Systems, MN.
Phospho-AKT (Ser 473) rabbit monoclonal antibody (cat. #4060), AKT (pan)
mouse monoclonal antibody (cat. #2920), LY294002 (PI3 Kinase Inhibitor)
(cat. #9901) were from Cell Signalling Technology®’MA.
6 Ckine (FL-134) rabbit polyclonal antibody (cat. #SC-25445), VEGF-C (C-20)
goat polyclonal antibody (cat. #SC-1881) were from Santa Cruz Biotechnology,
CA.

CKR7/CCR7 (N-term) rabbit monoclonal antibody (cat. #2059-1) was
purchased from Epitomics®, CA.
Odyssey blocking buffer (cat. #Q0391), goat anti-rabbit (cat. #3926-68021),
donkey anti-goat (cat. #926-68024), and donkey anti-mouse (cat. #926-68020)
IRDye polyclonal secondary antibodies were from LI-COR, NE.
Immobilon-FL PVDF membrane (cat. #IPFL10100), goat anti-mouse IgG, FITC
conjugate antibody (cat. #AP181F) and donkey anti-goat IgG, FITC conjugate
antibody (cat. #AP180F) were from Millipore, MA.
RNeasy MiniKit (cat. #74104) and RNase-Free DNase set (cat. #79254) were
purchased from QIAGEN, MD.
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Amaxa Cell Line Nucleofector Kit V (cat. #VCA-1003), Microvascular
Endothelial Cell Growth Medium EGM®-2-MV Bulletkit® (CC-3202) were
obtained from Lonza, MO.
TaqMan® Universal PCR Master Mix (cat. #4304437), TaqMan® PreDeveloped Assay Reagent, Hu GAPDH (cat. #1103172), TaqMan® Gene
Expression Assay, CCR7 probe (ID: 96261), TaqMan® Gene Expression Assay,
VEGF-C probe (ID: 992071), CCR7 Silencer® Select Pre-design siRNA (ID:
S3217), Silencer® Select Negative Control siRNA (cat. #4392420), High
Capacity cDNA Reverse Transcription Kit (cat. # 0810065) were purchased
from AB Applied Biosystems, CA.
GelRed™ Nucleic Acid Gel Stain (cat. #41002) was from Biotium, CA.
Cell Proliferation ELISA, BrdU (colorimetric) (cat. # 11647229001) was
purchased from Roche, IN.

2.2

Research Methodology

2.2.1

Cell Lines and Culture
Adult Human Dermal Lymphatic Microvascular Endothelial Cells (HMVEC-

dLyAd) (cat. # CC-2810T25) were obtained from Clonetics®/ Lonza (Walkersville, MO)
and maintained in an endothelial growth medium containing growth supplements
provided by the supplier ( EGM®-2-MV Bulletkit®, cat. # CC-3202, Lonza). The initial
expansion and subsequent passages (maximum of 5) were done according to the
manufacturer’s instructions.
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Human mammary MDA-MB-231 cells (passage # 3) from American Type
Culture Collection (ATCC) (Rockville, MD) were grown as a monolayer in RPMI 1640
medium (Invitrogen, Burlington, ON) supplemented with 10% fetal bovine serum, 100
U/ml penicillin, and 100 pg/ml streptomycin in a humidified incubator at 37°C with 5%
C 0 2.
2.2.2

Flow Cytometry Analysis

2.2.2.1

C CR 7 E xpression

To characterize the cell surface phenotype of CCR7 chemokine receptor, MDAMB-231 and HMVEC-dLy cells were grown up to 80-85% confluence in T75 flasks, and
then gently treated with a Trypsin-EDTA solution to facilitate the removal from the
substrate. Further, cells were incubated in complete medium for four hours on an ultra
low attachment cluster plate to enable the regeneration of the receptors. For staining
purposes, cells were then washed and resuspended in DPBS, supplemented with 0.5%
BSA and 0.01% NaN 3 ( sodium azide). The monoclonal anti-human CCR7 antibodies
were diluted in this buffer and used at a final concentration of 10 pl/ml for 45 minutes, at
4°C. After incubation, cells were washed with DPBS three times by centrifugation at 500
g for 5 minutes and labelled with R-Phycoerythrin conjugated IgG antibody for 30
minutes, at 4°C, in the dark. Following the final washing steps, 104 labelled cells were
analyzed on a FACS Calibur Cytometer (BD Biosciences) at the London Regional Flow
Cytometry Facility (Robarts Research Institute, London, On). FlowJo software version
7.6.5 (Treestar, Ashland, OR) was used for data analysis.

52
2.2.3

Western Blot Analysis

2.2.3.1

C C R 7 P rotein E xpression

MDA-MB-23I and HMVEC-dLy cells were plated at a concentration of
2xl05/well in six well plates and grown to near confluence. The day before protein
extraction, cells were placed in serum free media and incubated overnight. For the
analysis of the total cell lysates, cells were washed with ice-cold DPBS and treated with
M-Per lysies buffer supplemented with HALT protease inhibitor cocktail. After five
minutes of shaking on ice, cells were scraped from the wells and transferred to 1.5 ml
Eppendorf tubes. Lysates were sonicated (eight pulses, at level four) and then
centrifugated at 13,000 RCF for 20 minutes at 4°C, to remove cell debris. The
supernatants were collected and protein concentration was quantified in triplicate, using
the BCA protein assay kit following the manufacturer’s protocol. Fifteen micrograms of
total protein from the cell lysate was run per well on a 1.5 mm 10% SDS-PAGE gel
(polyacrylamide gel electrophoresis) at 90V (voltage) for one hours. The proteins were
then transferred to an Immobilon-FL PVDF membrane at 85V for two hours on ice
(semi-dry transfer). After the transfer, the membrane was blocked for one hour in a
blocking buffer which consisted of 60% TBS (20mM tris-base, 0.14M NaCl, pH 7.4) and
40% Odyssey blocking buffer. The membrane was then incubated with a mixture of
primary antibodies: rabbit monoclonal CCR7 (1:10000) and mouse monoclonal GAPDH
(1:5000), diluted in a solution of 60% TBST(20mM tris-base, 0.14M NaCl, 0.01%
Tween, pH 7.4) and 40% Odyssey blocking buffer overnight at 4°C. After being washed
in TBST (pH 7.4)(3 X 15 minutes), the membrane was probed with a mixture of goat
anti-rabbit (1:5000), donkey anti-mouse (1:10000) IRDye polyclonal secondary
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antibodies diluted in a solution of 60% TBST and 40% Odyssey blocking buffer, for two
hours in the dark. Finally, the membrane was washed three times (15 minutes each) in
TBST (pH 7.4) before scanning on an Odyssey infrared imaging system (LI-COR,
Lincoln, NE).

2.2.3.2

C C L21 P rotein E xpression

Western blot of CCL21 protein expression by MDA-MB-231 and HMVEC-dLy
cells was performed as in 2.2.3.1 with modification as followed. Fifteen micrograms of
total protein was electrophoresed per well on a 1.5 mm 12% SDS-PAGE gel at 80V for
two hours. The protein was then transferred to an Immobilon-FL PVDF membrane at 5V
for three hours (dry transfer). After the transfer, the membrane was blocked in 3% BSA
in TBST (20mM tris-base, 0.14M NaCl, 0.01% Tween, pH 7.4) for one hour at room
temperature. The membrane was incubated in a mixture of primary antibodies: rabbit
polyclonal antibodies against human 6Ckine (1:200) and mouse monoclonal GAPDH
antibody (1:5000) diluted in a solution consisting of 3% BSA in TBST overnight at 4°C.
The membrane was than washed three times in TBST (15 minutes each) followed by two
hours incubation in goat anti-rabbit (1:5000), donkey anti-mouse (1:10000) IRDye
polyclonal secondary antibodies diluted in 3% BSA in TBST (pH 7.4). Finally, the
membrane was washed three times (15 minutes) in TBST. The detection of CCL21 was
done in the same manner as described in 2.2.3.1.
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2.23.3

VEGF-C Protein Expression
MDA-MB-231 cells transiently transfected with CCR7 siRNA or control vector

were harvested 48 hours post-nucleofection and lysed in M-Per lysies buffer following
the protocol described in 2.2.3.1. Proteins (15 pg /well) from the cell lysates were
separated by 10% SDS-PAGE gel, transferred to an Immobilon-FL PVDF membrane at
5V for three hours. After the transfer, the membrane was blotted with a mixture of goat
polyclonal antibodies against human VEGF-C (1:500) and mouse monoclonal GAPDH
antibody (1:5000) diluted in 2% BSA in TBS (20mM tris-base, 0.14M NaCl, pH 7.4)
overnight at 4°C. The membrane was then washed three times in TBST (15 minutes each)
followed by two hours of incubation in donkey anti-goat (1:5000) and donkey anti-mouse
(1:10000) IRDye polyclonal secondary antibodies diluted in 2% BSA in TBS (pH 7.4).
Finally, the membrane was washed three times (15 minutes) with TBST. The detection of
VEGF-C was done in the same manner as described in 2.2.3.1.
2.2.3.4

Ph osph o-AKT Detection
To test whether CCL21 promotes the activation of AKT signalling pathway

downstream of CCR7, MDA-MB-231 cells were plated at 2xl05/well in six well plates.
The next day, cells were serum starved by culturing them in serum free RPMI overnight.
Prior to the protein extraction, cells were incubated in the absence (negative control) and
presence of recombinant human CCL21/6Ckine (350 ng/ml) over different time intervals
(5, 10, 15, 30, and 45 minutes). Also, to analyze the effect of blocking the CCR7
receptor, cells were treated with monoclonal anti-human CCR7 neutralizing antibodies
(1, 5, 10, 15 pg/ml) for two hours before stimulation with human CCL21/6Ckine (350
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ng/ml) for 30 minutes. Western blot analysis of the total cell lysates was then performed
as in 2.2.3.1 with the following modification. For analysis of the total cell lysates, cells
were washed with ice-cold DPBS and treated with M-Per lysies buffer supplemented with
Phosphatase Inhibitor Cocktail 2 (10 pl/ml) and Phosphatase Inhibitor Cocktail 3 (10
pl/ml). Fifteen micrograms of the total protein from the cell lysates was run per well on a
1.5mm 10% SDS-PAGE gel at 90V for 1 hour. The proteins were then transferred to an
Immobilon-FL PVDF membrane at 85V for two hours on ice. After the transfer, the
membrane was blocked for one hour in a blocking buffer consisting of 60% TBS (20mM
tris-base, 0.14M NaCl, pH 7.4) and 40% Odyssey blocking buffer. Immunoblotting was
performed with the following primary antibodies: Akt (pan) mouse monoclonal antibody
(1:500), Phospho-Akt (Ser473) XP rabbit monoclonal antibody (1:500) diluted in a
solution consisting of 60% TBST(20mM tris-base, 0.14M NaCl, 0.01% Tween, pH 7.4)
and 40% Odyssey blocking buffer overnight at 4°C. Blots were washed three times with
TBST and probed afterwards with the following IRDye polyclonal secondary antibodies:
donkey anti-mouse (1:10000) and goat anti-rabbit (1:5000) diluted in 60% TBST and
40% Odyssey blocking buffer before detection.

2.2.3.5

D ensitom etry

For quantitative analysis of the protein levels, NIH Image J (National Institutes
of Health) software was used to determine the average density of each band. For each
condition, the band density of analyzed protein was normalized to the band density of the
house keeping gene (GAPDH) or to the corresponding total protein (total-AKT).

56
2.2.4

Real-Time Polymerase Chain Reaction Analysis

2.2.4.1

CCR 7 mRNA Expression
For RNA extraction and cDNA synthesis, cells were grown up to 80-85%

confluence, trypsinized and collected as a cell pellet, then gently washed with DPBS
prior to lyses. Total RNA was extracted with RNeasy Minikit following the
manufacturer’s instructions. In order to eliminate genomic contamination, DNase
digestion was performed (RNase-Free DNase kit). The total RNA was quantified with a
spectrophotometer (NanoDrop 2000, Thermo Scientific) and cDNA was synthesized with
a High Capacity cDNA Reverse Transcription kit using up to 2 pg of total DNase-treated
RNA per 20 pi volume reaction. Reverse transcription was performed in a thermal cycler
(C1000™, Bio Rad) under the following parameters: 25°C for 10 minutes, 37°C for 120
minutes, followed by 85°C for 5 minutes. Primers for the human CCR7 chemokine
receptor and housekeeping gene (GAPDH) were synthesised at the University of Western
Ontario’s Oligo Factory (London, ON). Their product sizes were as follows: CCR7 PCR
product,

forward

5'-GACCGATACCTACCTGCTCAACC-3',

GCTCACTGCTGCTCCTCTGG-3',341

bp,

GAPDH

and

reverse

5'-

PCR product,

forward

5’-

ACCACAGTCCATGCCATCAC-3’, and reverse 3’- TCCACCACCCTGTTGCTGTA5’,452 bp. Samples were analyzed using the Platinum PCR SuperMix High Fidelity. A
PCR reaction volume of 50 pi was prepared for amplification, including 2.2 pi primers,
and 2.8 pi of DNA template solution. PCR cycling conditions were specific to each
primer pair, consisting of initial dénaturation at 94°C for 60 seconds and then 28 cycles
of dénaturation at 94°C (30 seconds), annealing at 59°C (30 seconds), and extension at
72°C (45 seconds) for CCR7, and 20 cycles of dénaturation at 94°C (30 seconds),
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annealing at 55°C (30 seconds), and extension at 72°C (60 seconds) for GAPDH. Real
time PCR products were separated by electrophoresis (90V for 45 minutes) on 2%
agarose gel and visualized by GelRed Nucleic Acid Gel Stain using a gel imaging system
(Gel Doc™ XR System, Bio Rad).
2.2.4.2 CCL21 mRNA Expression
Real-time PCR for CCL21 mRNA expression was performed as in 2.2.4.1 with
the following modification. Primers for the human CCL21 chemokine ligand, synthesised
by the University of Western Ontario Oligo Factory (London, ON), and their product size
were

:

forward

5'-CGCAGCTACCGGAAGCAG-3',

and

reverse

5'-

CTGCCTGAGAGCGCTTGC-3',176 bp. Real-time PCR products were separated by
electrophoresis (90V for 1 hour) on a 2.5% agarose gel electrophoresis (90V for 1 hour)
and visualized by GelRed Nucleic Acid Gel Stain using a gel imaging system (Gel Doc™
XR System, Bio Rad).
2.2.43

VEGF-C mRNA Expression
Real-time PCR for VEGF-C was performed following the previously described

protocol (2.2.4.1) with the following modification. The primers for VEGF-C, synthesised
by the University of Western Ontario Oligo Factory (London, ON), and their product size
were:

forward

5’

CGGGAGGTGTGTATAGATGTG-3,

and

reverse

3’-

ATTGGCTGGGGAAGAGTTTG-5’, 583 bp. The cycling parameters for VEGF-C
consists of initial denaturation at 94°C for 60 seconds and then 28 cycles of denaturation
94°C for 30 seconds, annealing 56°C for 30 seconds, and extension 72°C for 45 seconds.
Real-time PCR products were separated on a 2% agarose gel electrophoresis (90V for 30
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minutes) and visualized by GelRed Nucleic Acid Gel Stain using a gel imaging system
(Gel Doc™ XR System, Bio Rad).
2.2.5

CCR7 siRNA Nucleotransfection
MDA-MB-231 cells were grown up to 80% confluence in T75 flasks and then

gently harvested from the substrate. The harvest cells, at a concentration of 106 cells/ml,
were distributed into certified cuvettes and transfected with 6 pM of either silencer pre
designed siRNA targeting CCR7 or silencer negative control siRNA (scramble siRNA)
using the Amaxa Cell Line Nucleofactor Kit and X-013 program according to the
manufacturer’s protocol. After nucleofection, cells were placed in an antibiotic freemedium and incubated at 37°C, 5% CO2 for 48 hours. The nucleofection efficiency was
assayed with quantitative real-time PCR, conventional real-time PCR, and Western blot.

2.2.6

Quantitative Real-Time Polymerase Chain Reaction Analysis

2.2.6.1

CCR 7 and VEGF-C Expression
MDA-MB-231 cells transiently transfected with CCR7 siRNA or control vector

were harvested 48 hours post-nucleofection and RNA was extracted with an RNeasy
Minikit following the manufacturer’s instructions. DNA was synthesized with a High
Capacity cDNA Reverse Transcription kit following the previously described protocol
(2.2.4.1). Quantitative real-time PCR was performed in single micro capillary tubes on a
LightCycler (Roche Diagnostic, Que.) with TaqMan® Universal PCR Master Mix for
both the control (TaqMan® Pre-Developed Assay Reagent, Hu GAPDH) and the target
gene expression primer probes (TaqMan® Gene Expression Assay, CCR7 probe and
TaqMan® Gene Expression Assay, VEGF-C probe). Twenty microliters of PCR reaction
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volume was prepared for the amplification, including 1 pi TaqMan primer probe, and 2
pi template DNA solution. The quantitative real-time PCR profile was 95°C/15 seconds
denature, 58°C/1 minute anneal-extension for 40 cycles.

2.2.6.2

C C R 7 a n d V E G F -C R ela tive Q uantification

Quantitative real-time PCR reactions were done in triplicate. Delta-delta Ct
method was employed. For delta Ct calculation, the cycle threshold (Ct) values of the
sample under investigation and reference (control) sample were normalized to the
endogenous housekeeping gene (GAPDH). Delta-delta Ct was then calculated by
subtracting ACt of the reference sample from ACt of the gene under investigation and
fold difference (2 -AACt) was obtained (Applied Biosystems).
2.2.7
2.2.7.1

Enzyme-Linked Immunosorbent Assay (ELISA) Analysis
C CL21 P rotein Secretion

In order to quantify CCL21 protein secretion from MDA-MB-231 and
HMVEC-dLy cells, both cell lines were maintained in 2D and 2D-matrix culture
conditions. The cells grown in T75 flasks were serum starved overnight, trypsinized and
suspended in serum free media at a concentration of 6x104 cells /ml. For 2D samples,
cells were seeded onto six-well plates and basal conditioned media was collected after 24
hours culture. For 2D-matrix samples, GFR Matrigel was diluted in cold basal medium
(1:1 dilution) and added to the six-well plates (250 pi of GFR Matrigel/well) and allowed
to solidify for 30 minutes. Cells were then seeded on the solidified Matrigel and
incubated for 24 hours. After culture, the apical compartment (basal medium) was
collected and the Cell Recovery Solution (2 ml/well) was added to the cells and
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subcellular matrix together to digest the Matrigel matrix. After the matrix was completely
dissolved, the solution containing cells and matrix was centrifugated for five minutes at
1500 RPM. The supernatant, basal compartment was collected for further analysis and
the pellet, cellular compartment, was lysed with M-PER buffer (200 pl/well) for five
minutes. Lysates were sonicated (six pulses), then centrifugated at 13,000 RCF for 20
minutes at 4°C to remove cell debris, and the supernatants were collected. After
collection, the apical, basal, and cell compartments were analyzed for CCL21 by ELISA
(Quantikine Human 6Ckine Immunoassay) according to the manufacturer’s protocol.
Measurements were done in triplicate for two independent experiments. The optical
density at 570 nm and 450 nm was determined for each well using an Infinite M200
(TECAN) plate reader. Then the reading at 570 nm was subtracted from the reading at
450 nm for each well.

2.2.7.2

V E G F -C P rotein Secretion

To determine whether the activation of CCR7 signalling regulates VEGF-C
secretion, MDA-MB-231 cells transiently transfected with CCR7 siRNA or control
vector (scramble siRNA) were cultured in serum free media onto six-well plates and
treated with human CCL21/6Ckine (350 ng/ml) for 24 hours before supernatants were
collected for VEGF-C quantification. VEGF-C concentration in conditioned media was
measured by ELISA following the manufacturer’s instructions. Each measurement was
done in triplicate. The optical density at 570 nm and 450 nm was determined for each
well using an Infinite M200 (TECAN) plate reader.
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To determine whether the AKT signalling pathway regulates VEGF-C protein
secretion, MDA-MB-231 cells were grown in T75 flask to near confluence in complete
medium. Then, cells were serum starved by culturing in serum free RPMI overnight,
trypsinized and resuspended in serum free media to a final concentration of 106 cells/ml.
Cells were pre-treated with various concentrations of PI3 kinase inhibitor LY294002 (0,
0.5, 1, 1.5 pl/ml) for one hour before being plated onto six-well plates. Tumour cells
were then stimulated with human CCL21/6Ckine (350 ng/ml) and incubated at 37°C, 5%
CO2 for 24 hours. The next day, supernatants were collected and an ELISA was carried
out according to the manufacturer's protocol. Each measurement was done in triplicate.
The optical density at 570 nm and 450 nm was determined for each well using an Infinite
M200 (TECAN) plate reader.
2.2.8

Cell Proliferation ELISA, BrdU Assay Analysis

2.2.8.1

CCL21-Stimulated HMVEC-dLy Proliferation
To examine whether CCL21 stimulates HMVEC-dLy proliferation, cells were

grown up to 80% confluence in T75 flasks. HMVEC-dLy cells were then serum starved
overnight by culturing in an endothelial basal medium (EBM) without any growth
supplements, treated with a Trypsin-EDTA solution to facilitate removal from the
substrate, then resuspended in EBM to a final concentration of 2x104 cells/ml. Serumstarved cells were seeded onto 96-well tissue-culture microplates, stimulated with various
concentrations of human CCL21/6Ckine (0, 100, 200, and 350 ng/ml), and incubated at
37°C, 5% CO2 for 24 hours. After incubation, the quantification of cell proliferation was
performed by the measurement of BrdU incorporation in newly synthesized cellular
DNA, Cell Proliferation ELISA assay. HMVEC-dLy cells were labelled by the addition
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of BrdU labelling solution for two hours. During this labelling period, BrdU was
incorporated into the DNA of cycling cells. After removing the labelling medium, the
cells were fixed, and the DNA was denatured in one step by adding FixDenat. After
removing FixDenat, the anti-BrdU-POD antibody was added, and then bound to the BrdU
incorporated into the newly synthesized cellular DNA. The immune complexes were
detected by the subsequent substrate reaction. The reaction product was measured with a
plate reader, Infinite M200 (TECAN) at wavelength of 370 nm.

2.2.8.2

In h ibition o f C C L 21-Stim ulated H M V E C -dL y Proliferation

To determine whether CCR7 antibodies inhibit CCL21 induced HMVEC-dLy
proliferation, cells were harvested as previously described and pre-treated with various
concentrations of mouse monoclonal anti-human CCR7 antibodies (0, 5, 10, 20 pg/ml) in
EBM for two hours before being plated onto 96-well tissue-culture microplates. Human
CCL21/6Ckine (200 ng/ml) was added to each well and the system was incubated at
37°C, 5% CO2 for 24 hours. The following day, a cell proliferation ELISA assay was
performed according to the manufacturer’s protocol.
2.2.9

Boyden Chamber Assay Analysis

2.2.9.1

C CL21 -S tim u la ted H M V E C -dL y M igration

To establish the role of CCL21/CCR7 interaction on migration of lymphatic
endothelial cells (LECs), a Boyden chamber assay was performed using Trans-well
inserts. This assay consists of two chamber plates separated by a porous membrane.
Polycarbonate membrane inserts with 8 pm pore opening placed within 24-well plates
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were used. HMVEC-dLy cells were grown as described in 2.2.8.1. A two hundred
microliter suspension of serum-starved cells at a concentration of 2xlOs/ml was added in
the upper chamber of the cell culture inserts. Increasing concentrations of human
CCL21/6Ckine (0, 100, 200, and 350 ng/ml) were added to serum-free media in the lower
chamber. The assembled cell culture insert chambers were then incubated at 37°C, 5%
CO2 for different time periods (12, 24, and 48 hours). The cells were then fixed with
methanol and stained with eosin/thiasine. Direct microscopic counting at 40X
magnification (LEICA DFC 295) of the LECs that have migrated to the lower side of the
membrane was performed. Three independent experiments with each condition tested in
triplicate were conducted. For each sample, the cells in ten random high power fields
were counted and a mean value for each sample was calculated.

2.2.9.2

In h ibition o f C C L 21-S tim u latedH M V E C -dL y M igration

To test whether CCR7 antibodies inhibit CCL21 -induced HMVEC-dLy
migration, cells were harvested as previously described and pre-treated with various
concentration of the mouse monoclonal anti-human CCR7 antibodies (0, 5, 10, 20 pg/ml)
for two hours, before being seeded in the upper chambers. Human CCL21/6Ckine (350
pg/ml) in serum-free media was added to the lower chambers. The assembled cell culture
insert chambers were then incubated at 37°C, 5% CO2 for 24 hours. Direct microscopic
counting of the LECs that have migrated to the lower side of the membrane (after eosinthiasine staining) was performed. Three independent experiments with each condition
tested in triplicate were conducted. For each sample, the cells in ten randomly chosen
high power fields were counted and a mean value for each sample was calculated.
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2.2.10

Lymphatic Endothelial-Like Tube Formation Analysis

2.2.10.1 CCL21-Induced HMVEC-dLy Tube Formation
Tube formation assay is based on the ability of lymphatic endothelial cells to
form capillary like tube structures when cultured on a gel of basement extract. This assay
represents a simple, but powerful model to study the effect of either lymphangiogenic
activators or inhibitors on LECs’ properties (Berndt et al., 2008; Banziger-Tobler et al.,
2008; Cueni et al., 2009). To determine whether the CCL21/CCR7 interaction stimulates
lymphatic endothelial-like tube formation, HMVEC-dLy grown up in T75 flasks to near
confluence (80%) were trypsinized and resuspended in endothelial basal media + 0.5%
BSA (without any growth supplements) to a final concentration of 2x105 cells/ml. GFR
Matrigel was thawed overnight at 4°C, diluted with cold EBM (1:1 dilution) and placed
in six-well plates to solidify. HMVEC-dLy cells (2 ml of cell suspension) were seeded on
the solidified Matrigel and stimulated with various concentrations of recombinant human
6Ckine/CCL21 (0, 100, 200, 350, ng/ml). The system was incubated at 37°C, 5% CO2 for
24 hours and tube formation was examined on an inverted microscope at 100 x
magnification at different time intervals. Pictures were taken with a phase contrast Leica
(DFC340FX) camera at different magnifications (5X, 10X). Five images were randomly
taken in different areas of the wells by selecting fields of view that were distinct and
distant enough to not overlap with each other.
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2.2.10.2 In h ibition o f C C L 21-In du cedH M V E C -dL y Tube F orm ation

To test whether CCR7 antibodies inhibit CCL21 -induced HMVEC-dLy tubular
network formation, 2xl05cells/ml were harvest as previously described, and treated with
various concentrations of mouse monoclonal anti-human CCR7 antibody (0, 5, 10, 20
pg/ml) for two hours. Recombinant human 6Ckine/CCL21 (350 ng/ml) was then added
and cells were seeded onto the solidified Matrigel and incubated at 37°C, 5% CO2 for 24
hours. Pictures were then taken with the Leica EC3 camera. Five images were randomly
taken in different areas of the wells by selecting fields of view that were distinct and
distant enough to not overlap with each other.

2.2.10.3

L ym ph atic E n doth elial Tube Q uantification

The total length of the interconnected cells forming tubular structures was
measured with ImageJ (National Institutes of Health) software.
2.2.11

Statistical Analysis
Statistical calculations were performed using GraphPad Prism software version

5 (GraphPad Software, La Jolla, CA). All data were analyzed with one-way ANOVA
followed by Tukey’s multiple comparisons test, with the exception of densitometry data
which were analyzed with one-way ANOVA followed by Dunnetf s test. Data from
quantitative real-time PCR were analyzed with a Student’s T-test. Statistically relevant
differences between mean values were determined based on p < 0.05 criterion.

CHAPTER THREE:
RESULTS
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3.1

Expression of CCR7 Chemokine Receptor by MDA-MB-231 and
HMVEC-dLy Cells
Previous studies have reported that breast cancer cells express chemokine

receptors in a defined rather than in a random manner. Muller et al. (2001) analyzed the
mRNA expression of CCR7 receptor in several breast cancer cell lines and found that
CCR7 was highly expressed in metastatic cell lines, compared to low metastatic or
normal mammary epithelial cells. In this research, the constitutive expression of CCR7
chemokine receptor by MDA-MB-231 and HMVEC-dLy cell lines was analyzed at the
mRNA and protein levels.
Real-time PCR analysis showed that CCR7 chemokine receptor is expressed at
the mRNA level by both cell lines. CCR7 was detected at 341 bp and GAPDH was used
as an internal control (Figure 7).
To verify the expression of CCR7 protein, western blot analysis was performed.
The representative images shown in Figure 8A and the quantitative analysis in Figure 8B
demonstrate that CCR7 is expressed at the protein level by both cell lines analyzed.
GAPDH was used to control for equal loading. Blots shown are representative of three
independent experiments. CCR7 protein expression on the surface of both cell lines was
then assayed by flow cytometry. Data analysis revealed that 89.1% of MDA-MB-231 and
59.3% of HMVEC-dLy express CCR7 receptor. IgG isotype-PE was used as control
(Figure 9).
Based on these results, it can be concluded that CCR7 chemokine receptor is
expressed at the mRNA and protein levels by MDA-MB-231 and HMVEC-dLy cells.
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Figure 7. CCR7 Chemokine Receptor Is Expressed at the mRNA Level by MDAMB-231 and HMVEC-dLy Cells. Cells were cultured under standard conditions before
RNA extraction. Real-time PCR was performed using primers specific for human CCR7.
GAPDH was used as an internal control. Real-time PCR analysis demonstrates that
CCR7 receptor is expressed at the mRNA level by both cell lines. Representative results
from a series of three independent experiments are shown.
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Figure 8. CCR7 Chemokine Receptor Is Expressed at the Protein Level by MDAMB-231 and HMVEC-dLy Cells. A) Lysates from cultured MDA-MB-231 and
HMVEC-dLy cells were assayed by Western blot and CCR7 protein expression was
detected at 45 kDa. GAPDH (house-keeping gene) was used as an internal control.
B) CCR7 quantification through densitometry of Western blots revealed that the protein
level of CCR7 is 1.5 fold higher in tumor cells compared to lymphatic endothelial cells.
Data are represented as a mean normalized expression ± SD for three independent
experiments. (*) indicates significant difference (p < 0.05).
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Figure 9. CCR7 Chemokine Receptor Is Expressed on the Surface of MDA-MB-231
and HMVEC-dLy Cells. To characterize the cell surface phenotype of CCR7 receptor,
cells were analyzed through flow cytometry. The cyan histograms represent the
florescence activity of MDA-MB-231 and HMVEC-dLy cells after incubation with
phycoerythrin monoclonal antibody directed against CCR7. Red histograms denominate
the signal of the isotype control. Data analysis shows that 89.1% of MDA-MB-231 and
59.3% of HMVEC-dLy express CCR7 receptor.
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3.2

Expression and Secretion of CCL21 Chemokine Ligand by
MDA-MB-231 and HMVEC-dLy Cells
The CCL21 chemokine ligand is secreted as a 12 kDa protein that is readily

immobilized within the extracellular matrix by binding to sulfatated proteoglycans.
Recent findings (Shields et al. 2007; Shields et al., 2010) have reported that, in addition
to lymphatics, tumor cells are also responsible for the secretion of CCL21 chemokine.
Moreover, the production of CCL21 ligand by tumor cells was associated with the
presence of a slow interstitial flow towards lymphatics (Lazennec and Richmond, 2010).
In this research, CCL21 expression and secretion by MDA-MB-231 and HMVEC-dLy
cells were analyzed at the mRNA and protein levels.
Real-time PCR was performed using primers specific for human CCL21 and
showed that the chemokine ligand is expressed at the mRNA level by both cell lines
analyzed. CCL21 was detected at 176 bp and GAPDH was used as an internal control
(Figure 10).
The protein expression of CCL21 chemokine in MDA-MB-231 and HMVECdLy cells was analyzed by Western blot. The representative images of blots shown in
Figure 11A and the quantification of densitometry data in Figure 1IB indicate that
CCL21 is expressed by tumor cells while only traces of this ligand were observed in
lymphatic cells. Three independent experiments were conducted and GAPDH was used
as an internal control.
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Figure 10. CCL21 Chemokine Is Expressed at the mRNA Level by MDA-MB-231
and HMVEC-dLy Cells. Real-time PCR was performed using primers specific for
human CCL21. Agarose gel electrophoresis of real-time PCR products from MDA-MB231 and HMVEC-dLy cells showed the expected amplicon size (176 bp). GAPDH was
used as an internal control. Representative results from a series of three independent
experiments are shown.
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Figure 11. CCL21 Chemokine Is Expressed at the Protein Level by MDA-MB-231
Cells. A) Western blot analysis of MDA-MB-231 total cell lysates detected CCL21 at 12
kDa while only traces were observed in HMVEC-dLy. B) Densitometry analysis of
CCL21 expression in tumor and lymphatic cells. CCL21 band intensity from
densitometry of Western blots was normalized relative to GAPDH. Data are represented
as a mean normalized expression ± SD for three independent experiments. (*) indicates
significant difference (p < 0.05).
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CCL21 protein secretion was quantified from tumor and lymphatic cells using a
Human CCL21 Quantikine ELISA kit. For generation of conditioned media, cells in basal
media were plated onto 6-well plates coated with or without a growth factor-reduced
Matrigel matrix. Matrigel was used because CCL21 is strongly matrix-binding
particularly to sulphated proteoglycans. The bound CCL21 protein fraction was 3.7 fold
higher than the soluble fraction, as expected. On the contrary, HMVEC-dLy cells were
CCL21 negative, although previous studies have suggested that in vitro and in vivo
settings lymphatic cells secrete CCL21 chemokine (Figure 12).
To conclude, CCL21 chemokine ligand is expressed at the mRNA and protein
levels by MDA-MB-231 cells. On the other hand, no correlation was found between
CCL21 mRNA expression and protein expression/secretion in HMVEC-dLy cells.

.
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Figure 12. CCL21 Chemokine Is Secreted by MDA-MB-231 Cells. CCL21 protein
concentration in conditioned media was measured by enzyme-linked immunosorbent
assay (ELISA). Serum-starved cells were cultured onto 6-well plates coated with or
without Matrigel. The apical, basal, and cell compartments were then analyzed after
using Cell Recovery Solution for matrix digestion and M-PER buffer for cell lysis.
CCL21 secretion by tumor cells was 3.7 fold higher in 2D-matrix condition than in 2D
culture conditions, a result that was expected due to the matrix binding properties of this
chemokine. On the contrary, CCL21 protein secretion by HMVEC-dLy cells was
observed as being at very low levels. Data are represented as a mean ± SD (n = 3).
(*) indicates significant difference (p < 0.05).
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3.3

CCR7 Expression Regulates VEGF-C Secretion
The working hypothesis tested was that in CCR7 positive tumor cells the

secretion of lymphangiogenic factor VEGF-C is stimulated by CCL21/CCR7 interaction.
To demonstrate this, MDA-MB-231 cells were transiently transfected with 6pM of either
silencer siRNA targeting CCR7 gene or silencer negative control siRNA. The efficiency
of nucleofection was assayed using conventional real-time PCR, quantitative real-time
PCR, and Western blot. Cells transfected with scrambled siRNA and untreated cells were
used as controls. CCR7 siRNA effectively reduced the expression of CCR7 mRNA.
(Figure 13A, B). The product of Western blot for siRNA transfected MDA-MB-231 cells
has correlated with the result of the corresponding transcription profile (Figure 14A, B).

To determine whether CCR7 modulates VEGF-C gene expression, MDA-MB231 cells transiently transfected with CCR7 siRNA were harvested 48 hours postnucleofection and total RNA was extracted. Expression of the mRNA lymphangiogenic
factor VEGF-C was determined by conventional real-time PCR and quantitative real-time
PCR assays. Real-time PCR analysis revealed that low VEGF-C mRNA expression
translates in correspondingly reduced band intensity when compared with control
transfected cells. Also, compared to control-transfected MDA-MB-231 cells, CCR7
siRNA-transfected MDA-MB-321 cells showed a twofold decrease in VEGF-C mRNA
expression (Figure 15A, B)
Furthermore, to verify if transient transfection of siRNA against human CCR7
results in low levels of VEGF-C protein expression, MDA-MB-231 cells were harvested
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Figure 13. siRNA Against Human CCR7 Leads to Low Levels of CCR7 mRNA
Expression. MDA-MB-231 cells were transiently transfected with 6pM of either silencer
siRNA targeting CCR7 gene or silencer negative control siRNA. Total RNA was
extracted 48 hours after nucleofection and subject to : A) semi-quantitative real-time PCR
and B) quantitative real-time PCR. GAPDH was used as an internal control. Results for
quantitative

real-time

PCR

are

presented

in

relative

fold

change

(2'AACt) normalized to GAPDH. A four fold change in CCR7 mRNA expression was
observed in CCR7 knockdown cells with respect to scrambled knockdown cells. Data are
represented as a mean ± SD for three independent experiments. (*) indicates significant
differences (p < 0.05)) between treatment and control.
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Figure 14. siRNA Against Human CCR7 Results in Low Levels of CCR7 Protein
Expression. MDA-MB-231 cells transiently transfected with 6 pM of either silencer
CCR7 siRNA or negative control siRNA were harvested 48 hours post-nucleofection.
Cell lysates were then prepared and analyzed by: A) Western blot and B) densitometry.
siRNA reduced the expression of CCR7 protein in knockdown cells by two fold when
compared to scrambled knockdown cells. GAPDH was used as a loading control.
Densitometry data are represented as a mean ± SD for three independent experiments. (*)
indicates significant differences (p < 0.05) between treatment and control.
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Figure 15. siRNA Against Human CCR7 Results in Low Levels of VEGF-C mRNA
Expression. MDA-MB-231 cells transiently transfected with CCR7 siRNA or negative
control siRNA at 6 pM concentration were harvested 48 hours post nucleofection and
total RNA was extracted. Gene expression of the lymphangiogenic factor VEGF-C was
determined by A) semi-quantitative real-time PCR and B) quantitative real-time PCR.
Real-time PCR analysis revealed that low VEGF-C mRNA expression in CCR7
transfected cells translates in correspondingly reduced band intensity when compared
with control, transfected cells. Also, a two fold change in VEGF-C mRNA expression
was observed in CCR7 knockdown cells with respect to control. Results for quantitative
real-time PCR are presented in relative fold change (2"AAtt) normalized to GAPDH. Data
are represented as a mean ± SD for three independent experiments. (*) indicates
significant differences (p < 0.05) relative to control.
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48 hours post nucleofection and cell lysates were prepared and analyzed by Western blot
and densitometry. Intracellular VEGF-C protein expression was detected at 80 kDa.
GAPDH was used as an internal control. The protein level of VEGF-C in CCR7
knockdown cells decreased by 2.6 fold when compared to control scrambled knockdown
MDA-MB-231 cells. Densitometry data are from three independent experiments (Figure
16A, B).
To determine whether the CCL21/CCR7 interaction regulates the secretion of
lymphangiogenic factor VEGF-C, MDA-MB-231 cells transiently transfected with CCR7
siRNA were cultured in serum-free media and treated with human CCL21/6Ckine (350
ng/ml) for 24 hours. Cells transfected with scrambled siRNA and untreated cells were
used as controls. VEGF-C concentration in conditioned media was then measured with
ELISA by using VEGF-C Quantikine Immunoassay. Relative to resting culture, VEGF-C
secretion by MDA-MB-231 in response to CCL21 stimulation increase two fold. The
secretion level of VEGF-C from CCR7 siRNA transfected and CCL21 treated cells
decreased three fold compared to CCL21 treated cells (Figure 17).
Overall, these findings suggest that CCL21/CCR7 pair has the potential to
regulate VEGF-C expression/secretion in MDA-MB-231 cells.
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Figure 16 siRNA Against Human CCR7 Results in Low Levels of VEGF-C Protein
Expression. MDA-MB-231 cells transiently transfected with either silencer CCR7
siRNA or negative control siRNA were harvested 48 hours post-nucleofection. Protein
sample were collected, separated by 10% SDS-PAGE and analyzed by: A) Western blot
and B) densitometry. VEGF-C protein levels in knockdown cells decreased by 2.6 fold
when compared to control, scrambled knockdown cells. GAPDH was used as a loading
control. Densitometry data are represented as a mean ± SD for 3 independent
experiments. (*) indicates significant differences (p < 0.05) between treatment and
control.
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Figure 17. CCL21/CCR7 Chcmokinc Pair Regulates VEGF-C Protein Secretion.
MDA-MB-231 cells transiently transfected with CCR7 siRNA or negative control siRNA
were cultured in serum-free media and treated with human CCL21/Ckine (350 ng/ml) for
24 hours. The level of VEGF-C protein secretion was then measured through ELISA by
using human VEGF-C Quantikine Immunoassay. The optical density of each well was
determined using a plate reader by substracting the reading at 570 nm from the reading at
450 nm. VEGF-C content of CCR7 siRNA transfected cells decreased by three fold when
compared to the control group. Data are represented as a mean ± SD (n = 3). Different
superscripts indicate statistically significant differences, while shared superscripts are
assimilated with no statistical differences (p < 0.05).
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3.4

CCR7 Activation Regulates VEGF-C Secretion via the AKT
Signalling Pathway
The working hypothesis tested was that the CCL21/CCR7 axis regulates VEGF-

C secretion through the AKT signalling pathway. CCR7 activation has been positively
correlated with signalling through phosphatidylinositol 3-kinase (PI3K) and its
downstream mediator protein kinase B (AKT) as a pathway involved in: a) upregulation
of antiapoptotic proteins and downregulation of proapoptotic proteins; b) evasion of the
immune surveillance; and c) promotion of tumor cell mobility (Mburu et al., 2006;
Sanchez-Sanchez et al., 2004; Kim et al., 2005). In order to investigate the mechanism by
which the CCL21/CCR7 axis is involved in the regulation of VEGF-C secretion, the
phosphorylation status of AKT signalling pathway after CCR7 activation was assessed
through Western blot, and VEGF-C protein concentration was quantified through ELISA.
To test whether CCL21 promotes the activation of the AKT signalling pathway,
downstream of CCR7, serum-starved MDA-MB-231 cells were stimulated with human
CCL21/6Ckine (350 ng/ml) at various time intervals and then the amount of
phosphorylated AKT was analyzed within the cell lysates. Phosphorylation of AKT at
Ser 473 increased after five minutes of stimulation with CCL21. An increase in the
phosphorylation status of AKT was evident for the entire duration of stimulation,
suggesting that the CCL21 chemokine promotes AKT activation. Phosphorylation of
AKT was also observed in untreated cells, a faint band in the lane containing cell lysates
under serum-free conditions, suggesting the existence of an autocrine signalling loop.
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Densitometry data revealed that AKT reached maximum phosphorylation at five minutes
of stimulation compared to the control level (Figure 18A, B).
To verify whether CCR7 antibody blocks CCL21 induced AKT activation,
serum-starved MDA-MB-231 cells were pre-treated with various concentrations of CCR7
neutralizing antibody (1, 5, 10, 15 pg/ml) before stimulation with CCL21/6Ckine (350
ng/ml). Equal amounts of protein were then subjected to Western blot analysis. When
whole cell lysates were immunoblotted for phosphorylation of AKT, the pre-treatment
with CCR7 specific MAb was associated with a decrease in AKT phosphorylation at Ser
473. Densitometry data confirmed that inhibition of CCL21-induced phosphorylation of
AKT occurred in the presence of high concentration of CCR7 antibody. Lower
concentration of CCR7 antibodies showed inhibition of AKT to a lesser extent, and this
inhibition was not statistically significant (Figure 19A, B).

Figure 18. CCL21 Induces Phosphorylation of AKT at Ser 473 in MDA-MB-231
cells. Cells were serum starved for 24 hours before stimulation with human
CCL21/6Ckine (350 ng/ml) for various amounts of time (5, 10, 15, 30, and 45 minutes).
Cell lysates were then prepared and analyzed by: A) Western Blot and B) densitometry.
Western blot analysis of MDA-MB-231 total cell lysates detected AKT at 60 kDa.
Phosphorylation of AKT was observed over the entire duration of stimulation.
Densitometry data revealed that phosphorylation of AKT was significantly induced at
five minutes of stimulation, and this effect was sustain over the entire duration of
stimulation. Total AKT confirmed the equivalent loading of lanes. Data are represented
as a mean ± SD for three independent experiments. (*) indicates significant differences
(p < 0.05) between treatments and control.
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Figure 19. CCR7 Antibody Inhibits CCL21-Induced Phosphorylation of AKT in
MDA-MB-231 Cells. Serum-starved MDA-MB-231 cells were pre-treated with varying
concentration of monoclonal anti-human CCR7 neutralizing antibodies (1, 5, 10, 15
pg/ml) for two hours before stimulation with human CCL21/6Ckine (350 ng/ml). Cell
\
lysates were prepared and analyzed by: A) Western Blot and B) densitometry. CCL21induced AKT phosphorylation of MDA-MB-231 cells was inhibited in the presence of
high concentrations of CCR7 antibody (10, 15 pg/ml). Lower concentrations of CCR7
antibody showed inhibition of AKT to a lesser extent, and this inhibition was not
statistically significant. Total AKT was used to verify equal loading. Data are represented
as a mean ± SD for three independent experiments. (*) indicates significant differences (p
< 0.05) between treatment and stimulation.
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Finally, the functional role of the AKT signalling pathway in the induction of
VEGF-C secretion was investigated. For this purpose, serum-starved MDA-MB-231 cells
were pre-treated with various concentrations of PI3 kinase inhibitor LY294002 (0, 25, 50,
and 75pM) and then stimulated with human CCL21 (350 ng/ml) for 24 hours. The
supernatants were collected and a VEGF-C Quantikine Immunoassay was performed.
PI3K inhibitor reduced VEGF-C protein secretion by three fold when compared with
CCL21 treated cells (Figure 20). To conclude, the CCL21/CCR7 chemokine pair seems
to induce phosphorylation of AKT in MDA-MB-231 cells. These results also support that
the activation of PI3K/AKT signalling pathway downstream of CCR7 is involved in the
regulation of VEGF-C secretion.

3.5

CCL21/CCR7 Axis Has Lymphangiogenic Potential

in V itro

Lymphangiogenesis is a complex process that consists of several different steps.
None of the in vitro cultures can undergo all the steps involved in lymphatic vessel
formation because each of them is able to analyze only one step at a time. Since it is
practically impossible to replicate all the steps involved in lymphatic vessel formation in
a single in vitro assay (Bruyere and Noel, 2010), the proposed research has replicated the
following ones: lymphatic endothelial cells activation through a proliferation assay,
migration through a Boyden chamber assay, and morphogenesis through a tube formation
assay.
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Figure 20. CCL21/CCR7 Chemokine Pair Modulates VEGF-C Secretion via AKT
Signalling Pathway. Serum starved MDA-MB-231 cells were treated with varying
concentrations of PI3K inhibitor LY294002 (0, 25, 50, and 75pM). After two hours
incubation, PI3K-treated cells were stimulated with human CCL21/6Ckine (350 ng/ml)
for 24 hours. The supernatants were then collected for VEGF-C Quantikine ELISA assay.
PI3K inhibitor reduced VEGF-C protein secretion by three fold compared to untreated
cells (SFM). Data are represented as a mean ± SD (n = 3). Different superscripts indicate
statistically significant differences (p < 0.05).
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BrdU colorimetric assay was performed to determine the effect of CCL21
chemokine on HMVEC-dLy proliferation. Serum-starved HMVEC-dLy cells were
treated with various concentrations of human CCL21/6Ckine for 24 hours before
quantification. The number of proliferating cells increased by 1.7 fold after stimulation.
The outcome is presented as percentages of BrdU incorporation and data are normalized
with respect to the control group. Each experimental condition was assayed in five
different wells and each study was carried out in triplicate (Figure 21).
To examine the consequences of blocking CCR7 signalling on cellular
proliferation, serum-starved LECs were pre-treated with various concentrations of CCR7
neutralizing antibodies before stimulation with 200 ng /ml CCL21 for 24 hours. The next
day, a cell proliferation ELISA was performed. CCL21-stimulated proliferation was not
affected at lower concentrations of CCR7 antibody (5 pg/ml). However, at a
concentration of 10 pg/ml CCR7 antibody, CCL21-induced lymphatic endothelial cell
proliferation decreased by 1.9 fold, to reach the serum free level. The outcome is
presented as percentages of BrdU incorporation and data are normalized with respect to
the control group. Each experimental condition was assayed in five different wells and
each study was carried out in triplicate (Figure 22). From these findings, it can be
inferred that CCL21 promotes HMVEC-dLy cell proliferation.
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Figure 21. CCL21 Promotes HMVEC-dLy Proliferation. Serum-starved HMVECdLy cells were plated onto 96-well tissue-culture microplates and stimulated with varying
concentrations of human CCL21/6Ckine (0, 100, 200, 350 ng/ml) for 24 hours. After
incubation, the quantification of cell proliferation was performed by the measurement of
BrdU incorporation in newly synthesized cellular DNA (Cell Proliferation ELISA assay).
The number of proliferating cells increased by 1.7 fold. Each experimental condition was
assayed in five different wells and the study was carried out in triplicate. Data are
presented as mean ± SD. Different superscripts indicate statistically significant
differences (p < 0.05) between treatments and control.

Relative BrdU Positive HMVEC-dLy

105

SFM

100ng/ml

200 ng/ml
CCL21

350ng/ml

106

Figure 22. CCR7 Antibody Inhibits CCL21-induced HMVEC-dLy Proliferation.
HMVEC-dLy serum-starved cells were pre-treated with varying concentrations of
monoclonal anti-human CCR7 neutralizing antibody (0, 5, 10, 20 pg/ml) for two hours
before stimulation with 200 ng/ml human CCL21. Cells were incubated at 37°C, 5% CO2
for 24 hours and cell proliferation ELISA was performed. CCL21-stimulated
proliferation was not affected at lower concentrations of CCR7 antibody (5 pg/ml).
However, in the presence of 10 pg/ml CCR7 antibody, CCL21 -induced lymphatic
endothelial cell proliferation decreased by 1.9 fold, to the serum free level. The outcome
is presented as percentages of BrdU incorporation normalized to the control group. Each
experimental condition was assayed in five different wells and each study was carried out
in triplicate. Data are presented as mean ± SD. Different superscripts indicate statistically
significant differences, while shared superscripts are assimilated with no statistical
differences (p < 0.05).
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To examine the effect of CCL21 chemokine on lymphatic endothelial cell
migration, transwell migration assays were performed. Initially, dose and time response
to CCL21 was determined. Following the time course experiments, the chemotactic
response of lymphatic endothelial cells to CCL21 was then analyzed. Serum-starved
HMVEC-dLy were placed on the top chamber of transwell migration inserts and allowed
to migrate for 24 hours. Various concentrations of CCL21 were used in the bottom
chambers as a chemotactic agent. The addition of CCL21 chemokine induced a 2.6 fold
increase in the number of migratory cells when compared with negative control (SFM
only) (Figures 23&24).
To test whether CCR7 antibody interferes with CCL21 -induced HMVEC-dLy
migration, serum-starved cells were treated with various concentrations of monoclonal
anti-human CCR7 neutralizing antibody for two hours, seeded into transwell inserts, and
stimulated with 350 ng /ml CCL21. The number of migrating cells decreased by 2.5 fold
in the presence of CCR7 antibody (5 pg/ml) when compared with those treated with
CCL21 alone ( Figure 25).
Taken together, these results suggest that lymphatic endothelial cells are capable
of responding to the chemokine gradients and migrate. CCR7 antibody is a potent
inhibitor of CCL21 induced HMVEC-dly migration.

Figure 23. Representative Images of the Migration Slices Obtained After 24 Hours
Incubation. HMVEC-dLy cells under different treatments were placed on the top
chamber of transwell migration inserts and allowed to migrate for 24 hours. Direct
microscopic counting of the lymphatic endothelial cells that have migrated to the lower
side of the membrane after eosin-thiasine staining was performed. Three independent
experiments with each condition tested in triplicate were conducted. For each sample,
cells in 10 randomly chosen high power fields were counted and a mean value for each
sample was calculated. Microphotographs were taken at 40X magnification.
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Figure 24. CCL21 Stimulates HMVEC-dLy Cell Migration. Chemotaxis of HMVECdLy cells was assessed in transwell migration assay. Serum-starved cells were seeded in
the upper chamber and increasing concentrations of human CCL21/6Ckine (0,100, 200,
and 350 ng/ml) were added to serum-free media in the lower chamber. The assembled
cell culture insert chambers were then incubated at 37°C, 5% CO2 for 24 hours.
Following ligand stimulation, lymphatic endothelial cells had a 2.6 fold higher capacity
to migrate than un-stimulated cells. Migration data are represented as a mean
± SD for three independent experiments with each condition being tested in triplicate.
Statistically significant differences (p < 0.05) in the means are indicated by different
superscripts.

112

SFM

100 ng/ml

200 ng/ml
CCL21

350 ng/ml

Figure 25. CCR7 Antibody Inhibits CCL21-Induced HMVEC-dLy Cell Migration.
HMVEC-dLy were pre-treated with CCR7 antibody (0, 5, 10, 20 pg/ml) for 2 hours
before being seeded in the upper chambers. Human CCL21/6Ckine (350 ng/ml) in serumfree media was added to the lower chambers. The assembled cell culture insert chambers
were then incubated at 37°C, 5% CO2 for 24 hours. All tested concentrations of CCR7
antibody decreased lymphatic endothelial cells migration almost to the same degree.
However, peak inhibition was observed for 5 pg/ml CCR7 antibody, with a 2.5 fold
migration
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Lymphatic endothelial-like tube formation assay was performed to verily
whether the CCL21/CCR7 pair has the ability to stimulate the formation of tube-like
structures when cultured on a gel of a basement extract. HMVEC-dLy in serum freemedia were treated with varying concentration of human CCL21/6Ckine and incubated
for 24 hours on a Matrigel substrate. Pictures were taken after the first four hours of
incubation. HMVEC-dLy form perfect tubular networks in the presence of CCL21 and
the extent of tube formation increased with increasing concentration of CCL21.
Lymphatic endothelial cells grown in the presence of 350 ng /ml CCL21 formed 3 times
more tubes than lymphatic endothelial cells grown alone. However, little tube formation
was present in the absence of CCL21, under serum-free conditioned. These findings
suggest that HMVEC-dLy have in fact an intrinsic capacity to form tubular networks and
this capacity can be stimulated by CCL21 chemokine (Figure 26A, B).
To verily whether CCL21-stimulated acquisition of a lymphatic endothelial
phenotype was mediated by CCR7, HMVEC-dLy were treated with various
concentrations of CCR7 neutralizing antibody for two hours before being stimulated with
human CCL21/6Ckine (350 ng/ml) and incubated on a Matrigel substrate for 24 hours.
Pictures were taken after four hours of incubation. Tubular network formation was
blocked in the presence of CCR7 antibody, with a peak of inhibition at 20 pg/ml
antibody. These results suggest that CCR7 antibody is a potent inhibitor of CCL21induced lymphatic endothelial like tubular formation (Figure 27A, B).
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Figure 26. CCL21 Stimulates Tubular Network Formation by HMVEC-dLy.
HMVEC-dLy cells in serum free-media were treated with various concentration of
human CCL21/6Ckine (0, 100, 200, 350, ng/ml) and incubated for 24 hours on a Matrigel
substrate. A) Representative micrographs of tubular network formation were taken after
the first four hours of incubation. B) Through quantification of the length of connected
cells forming tubular structures it was inferred that tube formation increase with CCL21
concentration. Quantification of the length of tubular structures in at least three fields was
determined using Image J. Total tube lengths are represented as a mean ± SD for three
independent experiments. Statistically significant differences (p < 0.05) in the means are
indicated by different superscripts.
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Figure 27. CCR7 Antibody Inhibits CCL21-Induced Tube Formation by HMVECdLy. Cells were treated with varying concentrations of CCR7 antibody (0, 5, 10, and 20
pg/ml) for 2 hours before stimulation with 350 ng/ml CCL21. Cells were seeded on sixwell plates coated with Matrigel and incubated for 24 hours. A) Representative pictures
of tubular network formation were taken after the first four hours of incubation. B) Tube
formation decreased with increasing concentrations of CCR7 antibody, peaking at 20
pg/ml. Quantification of the length of tubular structures in at least three fields was
determined using Image J. Total tube lengths are represented as a mean ± SD for three
independent experiments. Statistically significant differences (p < 0.05) in the means are
indicated by different superscripts.
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CHAPTER FOUR:
DISCUSSION
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4.1

Thesis Overview
Given the numerous potential inducers of lymphangiogenesis, the immediate

intention of this study was to investigate the mechanism underlying the activity of yet
another pro-lymphangiogenic factor, CCL21, in mediating VEGF-C secretion. Since past
studies in our laboratory have shown that the inhibition of known VEGF-C promoters
(COX-2) does not translate into absolute suppression of VEGF-C synthesis, this suggests
that alternate/compensatory production mechanisms might exist. While prior studies have
established that COX-2 expression by breast cancer cells regulates VEGF-C secretion via
EP1/EP4 receptors (Timoshenko et al., 2006) and increases CCR7 expression via
EP2/EP4 receptors (Pan et al., 2008), no direct connections were made between CCR7
signalling and VEGF-C expression/secretion.
Based on recent evidence outlining that: 1) the synergy between CCL21/CCR7
and VEGF-C/VEGFR-3 axes represents a major factor in breast cancer spread to distant
sites (Shields et al., 2007; Issa et al., 2009); 2) CCR7 overexpression correlates with
lymphatic vessel density and lymph node metastasis (Yu et al., 2008); 3) CCL21/CCR7
interaction constitutes a critical event in lymphangiogenesis associated with pancreatic
cancer (Zhao et al., 2011), the present study proposed that CCR7 signalling constitutes a
regulatory mechanism of VEGF-C mediated breast cancer-induced lymphangiogenesis.
In order to address this hypothesis, the study aimed to determine: 1) whether
CCR7 expression plays a regulatory role in VEGF-C secretion by breast cancer cells; 2)
the signalling mechanism underlying CCR7-mediated VEGF-C secretion; 3) whether
CCL21/CCR7 pair has lymphangiogenic potential in vitro.
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By employing a two-cell in vitro model, the present study established that
siRNA-mediated knockdown of CCR7 gene suppressed VEGF-C expression/secretion in
MDA-MB-231 breast cancer cells, indicating a direct role of CCR7 in VEGF-C
synthesis. Furthermore, since the phosphorylation status of AKT increased after CCR7
activation and PI3K inhibitor effectively reduced VEGF-C protein secretion, it was
asserted that PI3K/AKT signalling pathway is the intracellular mechanism of CCR7mediated VEGF-C synthesis. Finally, the lymphangiogenic potential of CCL21/CCR7
axis on HMVEC-dly was demonstrated through a sequence of 2D assays, exogenous
ligand-induced proliferation, migration, and tube formation, aiming to replicate important
stages of the lymphangiogenic process.

4.2

Characterization of the CCR7 Chemokine Receptor Expression
Two cell lines were employed as an in vitro model for the present study. The

MDA-MB-231 cell line, derived from the pleural effusions of a breast cancer patient and
characterized by an invasive phenotype, was selected for its ability to express/secrete
VEGF-C, thus making it suitable for use in this study. HMVECs-dLy, primary adult
human dermal derived lymphatic endothelial cells, were identified as lymphatic cells via
flow cytometry, being positive for podoplanin and CD31 but negative for smooth muscle
alpha-actin.
In the current research, the expression of CCR7 by MDA-MB-231 and
HMVEC-dLy cell lines was analyzed through flow cytometry, Western blot at the protein
level, and by real-time PCR at the mRNA level. The corroboration of the results
presented in Chapter 3 suggests that both MDA-MB-231 and HMVE-dLy cells express

123
CCR7 receptor at the protein and mRNA levels. This knowledge was essential for further
determination of CCR7 role in the secretion of VEGF-C by breast cancer cells as well as
for verification of the lymphangiogenic involvement of CCR7. Both phenomena are
regarded as consequences of CCR7 activation following CCL21 binding.
CCR7 is a seven transmembrane-domain G protein coupled receptor with
physiological role in immune cell migration, recruitment, and guidance towards draining
lymph nodes. Under physiological conditions, CCR7 expression is largely controlled by
the homeostatic balance between the cells and their surrounding microenvironment.
Under pathological conditions, CCR7 expression was established as consistently
upregulated both at the protein and mRNA levels in a distinct and non-random manner in
a broad panel of breast cancer cell lines (Muller et al., 2001). More recently, flow
cytometry analysis reiterated this finding in the context of fresh primary breast carcinoma
cells (Cunningham et al., 2010). While CCR7 expression in various mammary tumor
cells may vary, it is known that even low increases in the receptor expression can
markedly affect cellular responses to ligand binding (Vines et al., 2002). Since CCR7 was
typically found to be highly expressed in metastatic cell lines compared to low metastatic
or normal mammary epithelial cells, a logical connection was made with the intense
chemotactic and invasive activity involved in breast tumor dissemination.
While a wealth of studies showed that CCR7 is expressed by many types of
tumor cells, this is not the case of CCR7 expression by LECs. In fact, the detection of
chemokine receptors on human endothelial cells has been controversial (Salcedo et al.,
1999) and so far, it was typically confined to CXCL12/CXCR4 chemokine axis
involvement

in tumor-induced angiogenesis associated with various types of
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malignancies (Koshiba et al., 2000; Liu et al., 2008; Chu et al., 2009). The vast majority
of studies in this category relied on human umbilical vascular endothelial cells
(HUVECs) to perform their angiogenic assays. By contrast, a single study reported CCR7
expression by LECs in the context of breast cancer metastasis (Shields et al., 2007).
However, the analysis was, in this case, limited to immunostaining performed on human
dermal LECs isolated from neonatal foreskins.

4.3

Characterization of the CCL21 Chemokine Expression and
Secretion
The wide physiological distribution of CCL21, combined with its involvement

in immune cell colocalization within lymphatics, strongly endorsed CCL21’s active role
in metastatic spread of CCR7-positive breast tumor cells. This theory became even more
outline after Muller et al. (2001) found abundant homeostatic expressions of CCL21 in
lymph nodes, which explains the frequent incidence of lymph node métastasés in
mammary carcinomas.
In the present study, CCL21 expression and secretion by MDA-MB-231 and
HMVEC-dLy cells were analyzed at the protein and mRNA levels. Western blot analysis
of MDA-MB-231 total cell lysates detected CCL21 at 12 kDa while only traces were
observed in HMVEC-dLy. Moreover, CCL21 protein secretion in conditioned media was
quantified through ELISA and the same trend was observed. For generation of
conditioned media, cells in basal media were placed on a growth factor-reduced Matrigel
matrix. In this experiment, Matrigel was used because, unlike collagen, it has a rich
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content in sulfated proteoglycans (Kleinman and Martin, 2005) and this can be exploited
further for matrix-binding purposes of CCL21, due to its known affinity to proteoglycans.
One important aspect to be emphasized is that CCL21 chemokine ligand is
secreted as a small molecular weight protein that is readily immobilized within the
extracellular matrix by binding to sulfated proteoglycans (Patel et al., 2001). In fact, the
interaction of the chemokines with glycosaminoglycans (GAGs) seems to influence their
functionalities in several different ways: i) cell surface retention of chemokines by means
of GAGs facilitates generation of high localized concentrations of chemokines with role
in directional signalling (Johnson et ah, 2005); ii) chemokine oligomerization through
GAG binding is important for their in vivo activation (Johnson et ah, 2004); iii)
chemokine/GAG binding determines selective presentation of chemokines to their
receptors (Netelenbos et ah, 2002); and iv) chemokine/GAG binding enables chemokine
protection from enzyme degradation (Sadir et ah, 2004).
As such, it was no surprise that the determined bound CCL21 protein fraction
was about three fold higher than the soluble fraction. This finding is also consistent with
the physiological scenario in which CCL21 is secreted by lymphatics directly into the
basement membrane. This data has been confirmed by Shields et ah (2007), who
established that tumor cells can generate autologous gradients of CCR7 ligand by
secreting it into the extracellular matrix under the influence of slow interstitial flow.
Based on this, they have also suggested that CCL21 secretion by tumor cells themselves
rather than and/or in addition to their lymphatic production might be targeted
therapeutically to prevent the metastatic spread of primary breast tumors.
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On the other hand, by contrast with the surveyed literature (Nagira et al., 1997;
Hedrick and Zlotnik, 1997; Gunn et al., 1998) reporting that lymphatic cells are capable
of secreting CCL21 both in vitro and in vivo settings, HMVEC-dLy cells used in the
present study were determined as poor producers of CCL21 chemokine. One possible
explanation of this result could be the substantial changes in gene expression induced by
culture in primary cells that might be the cause of the loss, for instance, of LYVE-1
expression or CCL21 production (Sironi et al., 2006). Cell culture might therefore alter
some of the core features of LECs. The other possible explanation of the sparse CCL21
expression could reside in the sensitivity of the method used to detect it.
One option to correct the deficiencies of the currently employed method relies
on the analysis of CCL21 expression by LECs in a 3D microenvironment, since its
importance on chemokine signalling has been repeatedly emphasized in the past. From an
experimental perspective, this would translate into creation of more advanced replicas of
the biophysical setting, which should include slow interstitial flow conditions that are
regarded as essential for stimulation of the chemokine secretion by LECs.

4.4

The Role of CCL21/CCR7 Pair in Mediating VEGF-C Secretion
In contrast with their well-defined physiological role in the functionality of the

immune system, the pathological involvement of the chemokines in tumor progression is
much less understood. However, due to recent intense research efforts, it became more
and more clear that chemokines are some of the key players involved in tumor-induced
angiogenesis, lymphangiogenesis and metastasis.
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The present study has put forward the hypothesis that CCL21/CCR7 interaction
is in fact responsible for VEGF-C synthesis by CCR7-positive MDA-MB-231 breast
cancer cells. For this purpose, CCR7 expression was temporarily inhibited with siRNA
targeting the CCR7 gene in MDA-MB-231 cells. The effectiveness of the temporary
siRNA expression was assessed by means of conventional real-time PCR, quantitative
real-time PCR, and Western blot. Important decreases in CCR7 mRNA and protein
expression levels were observed in CCR7 gene silenced in MDA-MB-231 cells when
compared to control siRNA.

Furthermore, the impact of transient CCR7-gene silencing on VEGF-C mRNA
expression and intra/extracellular protein expression/secretion by MDA-MB-231 cells
was assessed 48 hours post nucleofection. Since real-time PCR, quantitative real-time
PCR, Western blot, and ELISA analyses performed have confirmed that the knockdown
of the CCR7 gene translates into decreased amounts of the lymphangiogenic factor
VEGF-C at all investigated levels, it can be affirmed that CCL21/CCR7 interaction might
constitute one of the mechanisms responsible for VEGF-C production in the analyzed
breast cancer cell line model.

When it comes to contribution of the CCL21/CCR7 axis in the development of
mammary malignancy, there are at least two areas in which this pair has shown to be
actively involved, often through VEGF-C-mediated signalling: lymph nodes metastasis
and immune response modulation (Shields et al., 2007; Shields et al. 2007b; Yu et ah,
2008; Pan et ah, 2008; Shields et ah, 2010). On the other hand, while there has been an
impressive body of research verifying VEGF-C involvement in lymphangiogenesis
and/or lymph node metastasis (Skobe et ah, 2001; Karpanen et ah, 2001; Mandriota et ah,

128
2001; Nakamura et al., 2005; Timoshenko et ah, 2006; Hirakawa et ah, 2007; Yu et ah,
2007; Guo et ah, 2009), only few prior studies emphasized VEGF-C/CCR7 correlations
with lymphangiogenesis (Yan et ah, 2004; Deguchi et ah, 2010). However, they were
performed in a clinical context, for a different type of cancer, and without attempting to
uncover the molecular mechanisms underlying their connection.

4.5

Signalling

Mechanism

of

the

CCR7-Mediated

VEGF-C

Secretion
Since a certain correlation between CCR7 activation and VEGF-C secretion has
been established, the next question to be answered by the present investigation was
related to the underlying mechanism responsible for CCR7-mediated VEGF-C synthesis
by MDA-MB-231 cells. The hypothesis that PI3K/AKT signalling pathway could be in
fact responsible for CCR7-mediated VEGF-C secretion was addressed.
While this assumption is absolutely new in the context of CCR7 chemokine
receptor, similar molecular mechanisms have confirmed to be true for insulin-like growth
factor-I receptor (IGFIR)-mediated secretion of VEGF-C in lung carcinoma (Tang et ah,
2003). In general, CCL21/CCR7 binding has shown to be responsible for increased
migration, invasion, and proliferation of tumor cells through different intracellular
signalling pathways.
Many prior studies seem to imply that a direct consequence of CCL21 binding
is constituted by the downstream activation of the G protein complex that will induce via G(3y subunits released - activation of the PI3K/AKT pathway (Stephens et ah, 1994).
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This particular intracellular signalling pathway has been associated in the past with
several types of genetic deregulations that are frequently present in a wide majority of
human malignancies like inhibition of intracellular pro-apoptotic/upregulation of pro
survival signals (Vivanco and Sawyers, 2002; Gershtein et al., 2007). Similar
mechanisms have also been related to the involvement of PI3K/AKT pathway in
lymphangiogenesis, in a VEGF-C/VEGFR-3 mediated manner (Makinen et al., 2001).
Moreover, Pan et al. (2008) reported that the PKA/AKT-dependent signalling was
involved in the induction of CCR7 expression by COX-2 in breast cancer cells. However,
they did not test whether P13K/AKT activation which is characteristic to EP4 receptor
(Fujino et al., 2003) was involved in CCR7 upregulation.
In order to test the working hypothesis of the current objective, the effect of
CCR7 stimulation on AKT phosphorylation was assessed through Western blot
performed on serum starved MDA-MB-231 cells at different time intervals. While the
increase in phosphorylation status of AKT was evident at all time points - and practically
proved that AKT is activated following CCL21 binding - the weak phosphorylation
response observed for untreated cells suggests that this signalling pathway might be
constitutively activated. This phenomenon might be interpreted as a consequence of the
autocrine loop that is perpetuated by the tumor cell-secreted chemokine ligand CCL21 or
other receptor-ligand interactions. Conversely, to verify whether CCL21-induced AKT
phosphorylation was mediated by CCR7, this receptor was blocked with increasing
concentrations of neutralizing antibody. The analysis of densitometry data has indicated
that the most effective inhibition of AKT phosphorylation occurred for the highest
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amount of CCR7 MAb tested. Taken together, these results show that PI3K/AKT is
indeed activated by CCL21/CCR7 binding.
Finally, the functional role of AKT signalling in induction of VEGF-C secretion
was investigated. For this purpose, following a two step treatment of MDA-MB-231 cells
with: i) PI3 kinase inhibitor at increasing concentrations; and ii) CCL21 chemokine
ligand, the VEGF-C protein secretion in conditioned media was quantified through
ELISA. Since the addition of PI3K inhibitor led to significant decreases in VEGF-C
secretion, it can be asserted that CCL21/CCR7 interaction induces VEGF-C secretion by
MDA-MB-231 cells via P13K/AKT intracellular signalling pathway.

4.6

The Role of CCL21/CCR7 Pair in the Induction of LECs
Proliferation, Migration, and Tubular Network Formation
As surveyed literature suggests, CCL21/CCR7 pair has multiple roles in tumor

development and progression (Takeuchi et al., 2004; Redondo-Munoz et al., 2008; Sun et
al., 2009; Shields et ah, 2007; Shields et ah, 2010). However, while the complete palette
of functionalities assumed by this chemokine axis in breast cancer is yet to be deciphered,
one of the newer theories links CCL21/CCR7 interaction with angiogenesis and
lymphangiogenesis in pancreatic cancer (Zhao et ah, 2011).
Given that the pro-lymphangiogenic effect of VEGF-C in breast cancer is well
acknowledged (Skobe et ah, 2001; Nakamura et ah, 2005; Timoshenko et ah, 2006;
Hirakawa et ah, 2007; Zhang et ah, 2008), it is reasonable to believe that CCR7-mediated
secretion of VEGF-C is responsible for the formation of new lymphatic vessels.
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However, in addition to the indirect pro-lymphangiogenic role assumed by CCL21
chemokine via VEGF-C secretion, the current study proposed that the lymphatic
development is also caused by the direct binding between CCL21 ligand and CCR7,
expressed on the surface of LECs.

As mentioned before, lymphangiogenesis is a complex and multistep process.
Since none of the existent in vitro assays can replicate all of its steps in a combined
manner, lymphangiogenesis is generally tested in vitro through separate assays, each
attempting to mimic different stages of the lymphangiogenic process (Bruyere and Noel,
2010). Within the limited scope of the current study, LEC “genesis” was simulated
through a succession of assays replicating the following lymphangiogenic steps: i)
proliferation; ii) migration; and iii) formation of tubular-like structures.

In order to quantify the effect of CCL21 on HMVEC-dLy proliferation, serumstarved cells were treated for 24 hours with various concentrations of chemokine ligand.
The proportion of nuclei that incorporated BrdU increased after CCL21 treatment by at
least 70% with respect to the control group. Conversely, when CCR7 signalling was
blocked with increasing concentrations of CCR7 antibodies, LEC proliferation was
overall decreased and peaked for 10 pg/ml CCR7 antibody, when it reached the serumfree level. Based on these two experiments, it can be inferred that CCR7 activation
through CCL21 binding constitutes an effective signalling pathway for LEC proliferation.
Further, to test the effect of CCL21/CCR7 interaction on HMVEC-dLy
migration, a Boyden chamber assay was devised. HMVEC-dLy cells responded to the
chemokinetic effect of CCL21 and migrated towards the transwell membrane.
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Conversely, when CCR7 receptor was blocked with various concentrations of CCR7
antibody, LECs migration was significantly inhibited. Interestingly, neither CCL21
stimulation nor CCR7 receptor blocking induced dose-dependent effects on HMVECdLy migration, a phenomenon that could be explained perhaps through chemokine
receptor saturation followed by its internalization and cell desensitization (Zimmermanm
et al., 1999), although the extent of this effect is somewhat unclear in case of CCR7positive immune cells (Bardi et al., 2001; Kohout et al., 2004).

Finally, the effect of CCL21/CCR7 binding on HMVEC-dLy morphogenesis
was analyzed. For this, serum-free HMVEC-dLy cells were treated with increasing
concentrations of CCL21 and incubated for 24 hours onto growth factor reduced
Matrigel. Image-based quantification of the tubular network lengths revealed that CCL21
ligand stimulates tube formation. However, the results also showed that tubulogenesis is
actually a constitutive process for HMVECs-dLy when placed on Matrigel matrix, since
they are able to form small lengths of tubular network even in the absence of external
stimulation with CCL21 ligand. Conversely, blocking of the CCR7 receptor has inhibited
in tubulogenesis, which means that HMVEC-dLy morphogenesis is indeed mediated by
CCR7 activation by its cognate ligand CCL21. Based on these results, it can be inferred
that within the framework of the investigated in vitro model, CCL21 assumed a direct
pro-lymphangiogenic role that is complemented by its indirect action via VEGF-C.
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4.7

Biological Implications
Despite the intense research efforts that have occurred over the decade that has

elapsed since the positive identification of the lymphatic markers, the role of
lymphangiogenesis in the complex pathology of tumoral processes in general, and in that
of breast cancer in particular, has just begun to emerge. According to the newer studies,
lymphatics have started to be reclassified as active, rather than passive conduits in cancer,
since they are able to fine tune the balance between peripheral tolerance and immunity
with strong implications on immune host responses to tumor invasion (Lund and Swartz,
2010).

However, when it comes to the molecular regulators of the lymphangiogenic
process, the overall picture is far from being complete and tends to permanently broaden
with many other types of interactions often placed outside of the conventional VEGF
family of the pro-lymphangiogenic factors (Norrmen et al., 2011). Among them, the
interplay between CCL21/CCR7 chemokine axis and VEGF-C has been recently
underscored as being central to the metastatic dissemination via lymphatics (Shields et
al., 2007; Issa et al., 2009). In this regard, the present study has added a new piece to this
“puzzle”, by emphasizing that a closed loop/circular communication exists between
CCL21/CCR7 and VEGF-C/VEGFR-3 axes in a sense that not only the paracrine activity
of VEGF-C promotes CCL21 secretion by LECs (Shields et al., 2009), but also CCL21
stimulates VEGF-C synthesis via PI3K/AKT intracellular signalling, at least in the
analyzed in vitro model. Since this bidirectional crosstalk between the aforementioned
axes has a proved effect on lymphangiogenesis, this study adds several new elements to
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the multifaceted role of CCL21/CCR7 chemokine pair in mammary malignancy (Figure
28).
Given the severity of the implications of pathological lymphatic vasculogenesis,
(Sleeman et al., 2009; Tammela and Alitalo, 2010; Schulte-Merker et al., 2011), any
efforts directed towards inhibition of its occurrence are fully justifiable. Chemokines are
holding much promise in this regard and a better understanding of their participation in
tumor biology will be undoubtedly beneficial for their further exploitation as potent
cancer therapy candidates, especially due to the pleoitropism of chemokine receptors
throughout the human body.
Since the effectiveness of blocking the CCL21 chemokine signalling has
already been scrutinized from a therapeutic perspective (Lanati et al., 2010), the value of
the present CCL21/CCR7-related results is apparent.

4.8

Possible Limitations of the Experimental Design
Perhaps the most important limitation of the proposed research approach resides

in the exclusive use of the in vitro techniques. However, this in vitro step is practically
indispensable for incipient examination and understanding of the underlying molecular
mechanisms related to CCL21/CCR7 chemokine pair functionality and its influence on
breast cancer-induced lymphangiogenesis.
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Figure 28. Schematic Model of the Crosstalk between VEGF-C/VEGFR-3 and
CCL21/CCR7 Axes. These two axes have been shown to influence breast cancer
progression by distinct, but complementary mechanisms: 1) VEGF-C produced by breast
cancer cells acts in an autocrine manner to increase tumor cells invasiveness by
increasing their proteolytic activity and motility; 2) VEGF-C also acts in a paracrine
manner to increase lymphatic endothelial cells secretion of CCL21; 3) the paracrine
secretion of CCL21 guides the CCR7-expressing tumor cells towards draining
lymphatics; and 4) CCL21/CCR7 interaction increases VEGF-C production by tumor
cells, thus amplifies their lymphangiogenic potential. In fact, CCL21/CCR7 chemokine
pair has been found to regulate lymphangiogenesis in two different ways: i) directly by
stimulation of the pro-lymphangiogenic traits of LECs; and ii) indirectly through
increasing the secretion of the lymphangiogenic factor VEGF-C by breast cancer cells.
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Another possible limitation of the study design is related to the employment of
2D only cultures in lymphangiogenesis assays. By contrast with 2D cultures, that are
required to address separately the steps involved in lymphatic vasculogenesis, a more
enhanced type of 3D culture could have been employed. The 3D LEC culture can be
regarded as an intermediate/complementary step between in vitro and in vivo assays that
enable the avoidance of the typical inflammatory reactions associated with the latter type
(Bruyere and Noel, 2010).

4.9

Future Directions
In order to address the aforementioned limitations of the present study,

additional work could be performed to increase the strength of the acquired results and
thereby the level of confidence in the hypothesis being tested. The first possible step in
this direction could be comprised by the in vivo experiments. Further work will be
required to determine the most appropriate type of animal model for these investigations.
Once the most adequate animal model will be identified, the specific working hypothesis
to be tested is that CCL21/CCR7 axis acts as a promoter of tumor-associated growth and
lymphangiogenesis in vivo. For this purpose, tumor cells will be injected in the
experimental animals and the inhibitory effects of CCR7 antagonists on tumor growth
and lymphangiogenesis will be assessed through: i) tumor weight measurements,
ii) lymphatic endothelial markers, and iii) lymphatic endothelial microvessel density.
Another possible extension of the present work could aim to analyze CCR7,
CCF21, VEGF-C, and lymphangiogenic markers expression in a selective panel of
human breast cancer tissues collected at various phases of development of the primary
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mammary malignancy. The principal objective of this study would be the investigation of
possible correlations between these molecules and clinical stage/grade of breast tumor,
respectively.
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CHAPTER FIVE:
SUMMARY AND CONCLUSIONS
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5.1

Summary
Based on the results presented in Chapter 3, the following remarks can be made:
> CCR7 chemokine receptor is expressed at the protein and mRNA levels by the two cell
model analyzed in vitro (MBA-MD-231 and HMVEC-dLy);
> CCL21 chemokine is expressed at the protein and mRNA levels by the analyzed tumor
cells;

> CCL21 secretion by MDA-MB-231 is substantially higher in 2D-matrix conditions than
in 2D culture conditions;

> transient transfection with siRNA targeting human CCR7 chemokine receptor results in
reduced VEGF-C expressions at the mRNA and protein levels in MDA-MB-231 cells;
> knockdown of CCR7 chemokine receptor leads to a decrease in VEGF-C protein
secretion by MDA-MB-231 cells;
> CCL21 chemokine stimulates the phosphorylation of AKT at Ser 473 in MDA-MB-231
cells;

>

AKT phosphorylation was mediated by CCR7 activation since CCR7 antibody blocks
CCL21-induced phosphorylation of AKT in MDA-MB-231 cells;

> activation of the PI3K/AKT signalling pathway is involved in the regulation of CCR7mediated VEGF-C secretion;
> CCL21/CCR7 pair promotes proliferation and migration of HMVEC-dLy;
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> CCL21/CCR7 pair stimulates the formation of tubular network structures by
HMVEC-dLy.

5.2

Conclusions
This study reports the influence of CCL21 chemokine and its receptor on the secretion of

VEGF-C and elucidates the correlation between the CCL21/CCR7 axis and lymphangiogenesis.
Moreover, these results support the role of the PI3K/AKT signalling pathway in CCR7 mediated
VEGF-C secretion. It can also be reasoned that CCR7 positive tumor cells are capable of
secreting endogenous ligand and thereby propagating autocrine CCR7 activation.
The expression of functional CCR7 chemokine receptor by HMVEC-dLy suggests that
lymphatic endothelial cells are capable to respond to the chemokine gradients. In fact, the results
found support a positive role of the CCL21/CCR7 chemokine pair in lymphatic vessel formation,
including the ability to induce lymphatic endothelial cells proliferation, migration and to
stimulate tube formation. Based on these findings, it can be asserted that in the investigated
model, CCL21 is capable to assume a direct pro-lymphangiogenic role.
To conclude, corroboration of data presented in this study indicates that VEGF-C and
CCL21 display a significant crosstalk. In fact, CCL21/CCR7 chemokine pair has been found to
regulate lymphangiogenesis in two different ways: i) directly by stimulation of the prolymphangiogenic traits of LECs; and ii) indirectly through increasing the secretion of the
lymphangiogenic factor VEGF-C by breast cancer cells.
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